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ABSTRACT 
Adam Berkley Roberts: Selective Modulation of the Microbiome: Efforts Toward a New Paradigm in 
Human Therapeutics 
(Under the direction of Matthew Redinbo) 
 
Drug-induced toxicity, side effects of certain therapeutics, is often more toxic than the original 
disease and limits the potential for dose intensification. The dose-limiting side effect of the mainstay anti-
cancer therapeutic CPT-11, which is a prodrug for its active metabolite SN-38, is delayed onset diarrhea. 
Detoxified in the liver through conjugation with glucuronic acid, SN-38-glucuronide acts as a substrate 
for an enzyme, β-glucuronidase, expressed by the symbiotic microbiota naturally populating the 
mammalian gastrointestinal tract. Thus, bacterial β-glucuronidase inhibitors should alleviate the delayed 
onset diarrhea as a side effect of CPT-11. Initial high-throughput screen hits were established as potent 
inhibitors in biochemical assays against a range of β-glucuronidase enzymes from GI-associated bacterial 
species and as non-toxic to mammalian or bacterial cells. Importantly, they proved to be selective for the 
bacterial enzyme relative to the mammalian orthologue and proved effective in preclinical models of 
toxicity. X-ray crystallographic analysis of several inhibitors in complex with the bacterial enzymes 
highlighted structural features critical for inhibition. Exploiting these features, we were able to synthesize 
analogues from original screening hits that have since displayed improved in vitro and in vivo properties. 
These inhibitors are effective in models of drug-induced toxicity beyond CPT-11, including NSAID-
induced enteropathy in the small intestine. This work is designed to ultimately create a clinical co-therapy 
for drugs that are limited by their toxic GI side effects caused by bacterial β-glucuronidase. This appears 
to be a new paradigm of drug therapy – inhibition of a bacterial enzyme for therapeutic gain without 
harming the microbial symbiotes essential for human health.  
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Chapter 1 
Introduction 
 
1.1 Microbiome 
Recent technological advances have allowed researchers to uncover a deeper understanding of the 
symbiotic microbial populations in humans. Indeed, because microbial cells in the human body 
outnumber all other kinds of cells 9 to 1, one could argue that humans simply act as a large fermenter to 
the host microbes. Increasingly, this humorous turn-of-phrase is becoming more authentic. Our 
understanding of the genetic makeup of this microbial population, known as the microbiome, and the role 
it plays in maintaining a functioning metabolism in humans has sprouted into common knowledge with 
the work of several key laboratories and the introduction of the Human Microbiome Project, which 
sampled and sequenced the genetic material of the microbial populations of a representative sample of 
healthy adults. Much like the Human Genome Project before it, the Human Microbiome Project has laid 
the foundation to understand, and subsequently to predict, manage, manipulate and potentially prevent, if 
necessary, the host-microbe interactions that lead to poor health outcomes and disease.   
The completion of the Human Microbiome Project highlighted the complexity and diversity of 
the bacterial populations that reside in and on their human hosts. Not only do sample populations 
typically differ markedly between subjects, but also samples are typically rich and varied when taken over 
time from the same location in the same subject (1). The subjects in this comprehensive investigation 
were required to be “healthy” because researchers have begun to appreciate the role of the microbiota in 
maintaining a thriving metabolism and in the development of disease (2–4). Studies in germ-free mice 
indicate the critical role that the microbiota play in the development of the host lymphatic system, 
metabolic profiles, and neurochemical levels compared to wild-type controls (5–7). Gastrointestinal (GI) 
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complications are common in patients diagnosed with autism spectrum disorders (ASD), and a recent 
study using mouse models demonstrates that modulations of the GI microbiome contribute to the 
symptoms of ASD and that probiotic therapies can alleviate some of these symptoms (8). Alterations in 
the GI microbiota have also been implicated in the development of metabolic disorders (9, 10)  and have 
been similarly implicated in disease pathogenesis, such as in irritable bowel syndrome, type 1 and type 2 
diabetes, and cardiovascular disease (4, 11–13).  Healthy GI microbiota also play an important role in 
directly preventing bacterial infection (2, 3) and indirectly regulating the host immune function (5, 6, 14).  
These emerging data emphasize the importance of maintaining a diverse and healthy population of GI 
commensal bacteria and suggest significantly limiting the use of broad-spectrum antibiotics, which can 
significantly alter the diversity of the GI microbiota. They also facilitate new explorations into the on-
going chemical interplay between mammalian tissues and microbial symbiotes. At any given time, there 
are an innumerable amount of molecules in circulation that must be metabolized in order to promote a 
healthy physiology, and the mammalian microbiome plays a critical role. 
  
1.2 The Role of the Microbiota in Mammalian Metabolism 
Before compounds reach the intestine where they are impacted by the microbiota, they are 
typically metabolized in the liver. Accounting for ~75% of reactions, Phase I reactions are most notably 
and most often carried out by cytochrome P450 enzymes, which often oxidize compounds, leading to 
reduced toxicity (15). Phase II reactions involve conjugation of the lipophilic organic compound to 
charged or polar species, enhancing elimination. A major pathway involves the conjugation of a 
glucuronide from UDP-glucuronic acid to nucleophilic functional centers, such as oxygen in hydroxyl or 
carboxylic acid groups, catalyzed by UDP-glucuronosyltransferases (UGT). While this reaction often 
detoxifies xenobiotic compounds, metabolites such as morphine-6-O-glucuronide are active (16). This 
reaction is also critical for proper homeostasis of endobiotics, such as bilirubin and bile acids. 
Polymorphisms in UGT genes have been linked to hyperbilirubinemia associated with Crigler-Najjar and 
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Gilbert’s syndromes (17), and, in addition to other enzymes in the liver, such as methyl- and 
sulfotransferases that  play a critical role in Phase II reactions, to cancer (18).  
These conjugation reactions are intimately linked to activity of the microbiota through 
enterohepatic circulation. The microbiota will often reverse the conjugation reaction and liberate the 
parent compound to be reabsorbed and trafficked back to the liver. Although this process potentially 
affects xenobiotic metabolism, it is most notably important to the metabolism of endobiotics (19). A 
sufficient concentration of endobiotics in circulation must be maintained for homeostasis. For instance, 
bile acids are required for the proper processing of cholesterols and fats. Alterations in the GI microbiota 
leading to the dysregulation of bile acids in circulation can have wide-ranging effects from GI disorders 
and atherosclerosis to diabetes and obesity (20). Hydrolase enzymes expressed endogenously and by the 
GI microbiota have been implicated in reversing Phase II conjugation reaction.  
 
1.3 Glycoside Hydrolases 
 Carbohydrates play a critical role in a variety of cellular processes critical to a functioning and 
healthy metabolism, including detoxification of xenobiotics through conjugation. The unique repeating 
structure of carbohydrates, built up from simple sugars, allows for an almost endless array of 
combinations through the diversity of their bonds. Held together in a tight and efficient manner, it is 
critical to liberate the simple sugars from their complex chains for use as energy. It is, thus, not surprising 
that mammals express a wide range of enzymes that hydrolyze the assortment of glycosidic bonds that 
hold carbohydrates together. The family of enzymes mainly responsible for these hydrolytic reactions is 
known as the glycoside hydrolases. Genetic mutations in these enzymes have been implicated in a range 
of inherited diseases, and specific inhibitors are used as therapeutics (21). 
Resident microbial populations must scavenge for energy sources in order to survive. Thus, 
symbiotic bacteria also express an array of glycoside hydrolase enzymes, which process short-chain 
carbohydrates relative to their orthologous mammalian counterparts, in order to liberate the simple sugars 
as a source of energy (22). This process is orthogonally critical to the metabolism of compounds which 
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are often detoxified through conjugation with simple sugars. Contrary to the liver, which primarily 
metabolizes compounds through oxidation and conjugation, the human microbiota processes chemicals 
through counter reductive and hydrolytic reactions and plays a key role in the enterohepatic circulation of 
metabolized compounds including xenobiotic drugs and endobiotic molecules such as bile acids.  
 
1.4 β-Glucuronidase 
One key family member of the glycoside hydrolases is β-glucuronidase. Found in plants, animals, 
and microorganisms, these enzymes hydrolyze carbohydrates that contain a glucuronide moiety, releasing 
glucuronic acid and the parent aglycone molecule.  In humans, β-glucuronidase is isolated in lysosomes, 
acting as an acid hydrolase in glycosaminoglycan degradation (19). Researchers have also noted an 
increase in extracellular β-glucuronidase activity around tumors, stimulating new investigations into 
glucuronide prodrugs that could be liberated at the site of the tumor (23). In microbes, an orthologous 
form of β-glucuronidase is expressed in order to use passing glucuronidated compounds as an energy 
source. The general ubiquity of β-glucuronidase has allowed it to be used as a reporter gene in biological 
experiments and as a marker for microbial contamination (24, 25).  
Original research into microbial β-glucuronidase activity led to the conclusion that the activity 
was isolated to E. coli and other closely related species (26). Later research showed that it was expressed 
in a range of GI-associated species such as Bacteroides and Clostridium (27, 28). Although in some 
species, such as Bacteroides, the activity is much weaker, the species are also much more abundant, so it 
is believed that they still make a significant contribution to overall β-glucuronidase activity in the GI tract 
(27, 29). Indeed, the β-glucuronidase activity from Bacteroides has been attributed to a second, distinct 
gene (28).  
 Compounds are often detoxified in the liver through conjugation with glucuronic acid, so human 
and microbial β-glucuronidases play a key role in drug metabolism and disposition through the release of 
the parent compound. Indeed, interindividual changes in β-glucuronidase expression may alter the 
efficacy of glucuronidated compounds (30).  This process may lead to an increased risk of carcinogenesis 
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in the GI tract due to a buildup of carcinogenic compounds (31), but more often, it is associated with 
acute GI toxicity. 
 
1.5 Drug-Induced Toxicity 
Toxicities associated with most often chronic or, in some cases, acute drug use are a common 
problem affecting the entire length of the GI tract and has only recently been appreciated owing to 
advances in diagnostic technology (32). The effects can be wide-ranging, either in the location of the 
injuries to the GI tract or in the symptoms that they engender, from benign histologic changes to fatal 
perforations and bleeding. In addition to drugs currently on the market, there are surely more that never 
made it through clinical trials due to toxic side effects. 
Although the mechanisms of toxicities are not completely understood, the GI microbiota has 
largely been implicated. These bacteria play a critical role in a functioning metabolism owing to their 
considerable ability, perhaps as great as the liver, to process drugs that pass through the GI tract (33). 
Owing to the increasingly biopharmaceutical complexity of new drugs, potential therapeutics often suffer 
from poor solubility. This leads to an increase in the amount of drug that passes through the lower GI tract 
and then interacts with the resident microbiota. Thus, the interaction between potential therapeutics and 
the host microbiota should be thoroughly explored in any proper drug development process. 
Sorivudine is the foremost example in the dangers in unforeseen drug-induced toxicities. Use of 
sorivudine indirectly caused the death of at least eighteen patients soon after it was approved for use in 
Japan. Unbeknownst to researchers, sorivudine was metabolized by GI microbiota and its metabolite 
inhibited the biotransformation of the potent chemotherapeutic 5-flourouracil, leading to a severely toxic 
buildup (34). This tragic episode highlights the importance of understanding how new therapies are 
metabolized by GI microbiota and has led to the development of new models and screens in preclinical 
trials. In response to drugs currently on the market, researchers are searching for paths to limit toxicity, 
and they are beginning to target the GI microbiota. 
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1.6 CPT-11 
 Extracted from the Asian tree Camptotheca acuminata, camptothecin was first identified in 1966 
as a drug with potential anti-tumor efficacy. Preclinical trials revealed activity in gastric and colonic 
tumors, so camptothecin was developed as a therapy for GI malignancies (35). Although preclinical data 
was promising, the development of camptothecin was hampered by poor solubility and toxic side effects 
(36). These toxicities along with poor efficacy in phase II trials led to the abandonment of camptothecin 
as a therapy. In 1985, following the recognition of the role of topoisomerase I in DNA replication, 
camptothecin was found to target topoisomerase I and cause reversible single-strand breaks. After the 
replication fork collides with the stalled enzyme, these reversible breaks become irreversible double-
strand breaks, ultimately leading to apoptotic cell death (35). Although camptothecin still suffered as a 
potential therapeutic, investigators began to explore and exploit the main scaffold in order to improve 
solubility, mitigate toxic effects, and maintain anti-tumor efficacy. 
This led to the development of numerous analogues of camptothecin, including CPT-11 
(irinotecan, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]). CPT-11 was the first water-soluble derivative of 
camptothecin to be developed. It maintained potent anti-tumor activity for GI malignancies and gained 
approval for use in the US by 1996 (35). Today, CPT-11 is utilized worldwide for the treatment of a 
variety of solid malignancies, but its efficacy is often limited by severe GI toxicity (37–44). CPT-11 is 
most frequently employed in first- and second-line treatment of metastatic colon cancers, both alone and 
in combination with other agents (45, 46). Treatment for colorectal cancer is based on the stage and 
progression of the disease. If diagnosed early, surgery alone can be effective, but upon metastasis, 
radiation and chemotherapy become essential. Single-agent treatment with CPT-11 after first progression 
significantly increases survival time compared to other options, such as fluorouracil, combination 
fluorouracil/leucovorin, or supportive-care (47). In addition to colorectal cancer, CPT-11 has now been 
employed in preclinical and clinical trials against a range of other malignancies, including brain tumors 
and lung, breast, gastric, pancreatic, and gynecological cancers (48–54).  
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CPT-11, like its predecessor camptothecin, is not without side effects. Patients receiving this 
chemotherapy suffer from numerous toxicities, the most common and significant of which are 
myelosuppression and diarrhea. Diarrhea can occur early or late (beyond 24 hours post infusion), affects 
up to 40% of patients, and limits the dose that the patient can receive (37, 38, 40, 42, 44, 55). While most 
early onset diarrhea associated with CPT-11 treatment can be treated with anti-motility agents, the 
delayed GI toxicity is refractory to standard treatments (56).  
 CPT-11 is unique from other derivatives of camptothecin in that it contains a bulky dipiperidino 
side-chain in addition to the characteristic five-ring scaffold of camptothecin (Figure 1.1). Thus, CPT-11 
is considered a prodrug that is processed by carboxylesterase (CE) enzymes that remove the dipiperidino 
side chain following intravenous (IV) administration to produce, SN-38, which is thought to produce the 
majority of the antitumor activity in the same manner as camptothecin, by targeting the human 
topoisomerase I catalytic cycle (57–59). The metabolic fate of SN-38 is further regulated by UGTs in the 
liver and other tissues.  UGT isoforms, in particular UGT1A1, catalyze the conjugation of a glucuronide 
group onto SN-38, producing the inactive compound SN-38 glucuronide (SN-38G), which is marked for 
elimination through the GI tract (60). However, as SN-38G passes through the GI tract, it acts as a 
substrate for bacterial β-glucuronidases, which remove the glucuronide moiety, regenerating the active 
metabolite SN-38 in the GI lumen. SN-38 can then impact intestinal epithelial cells, mediating cell death 
and producing the severe, delayed diarrhea that limits the efficacy and dose-intensification of CPT-11 
(61–63). Indeed, the severity of CPT-11-induced diarrhea is correlated with levels of SN-38 in the 
intestinal lumen, and the intestinal microbiota have been found to play a significant role in the 
development of this toxicity (58, 63, 64). It has now been convincingly demonstrated that the intestinal 
toxicity of CPT-11 limits dose intensification and optimized delivery of CPT-11 (65–67). 
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1.7 Potential Therapies 
 This research is not the first attempt to improve the outcome of CPT-11 treatment. Other 
strategies have included pharmacologic modification (68), antibiotics targeted at host microbiota (40), 
intestinal alkalinization (69, 70), or pharmacogenetic screening (55, 60). None of these strategies were 
effective, however. A specific, nontoxic solution has yet to be realized. Attempts to produce SN-38 
analogues have been in production for nearly a decade and are not devoid of GI toxicity (68). Antibiotics, 
while successful at lessening the side effects, also harm the patient due to the role that the microbiota 
plays in nutrient and bile metabolism and protection against pathogenic infection. This role is even more 
critical in CRC patients already immune-compromised.  Intestinal alkalinization, although effective at 
alleviating late-onset diarrhea, affects the pharmacokinetic profile of CPT-11 such that the patient 
receives less CPT-11 and SN-38 in systemic circulation (71). Screening of the UGT1A1 promoter, which 
is responsible for polymorphisms in UGT enzymes and ultimately varying levels of glucuronidation, 
allows for dose reduction in patients that are more susceptible to side effects (72). Still, this method is not 
a prophylaxis and not effective as a treatment for the general population.  
 
1.8 Alleviation of CPT-11-Induced Toxicity 
 The lab of Dr. Matthew Redinbo (UNC Chapel Hill) tackled the problem of CPT-11-induced 
toxicity by developing a system of targeted inhibition of bacterial β-glucuronidase. Known β-
glucuronidase inhibitors were not potent enough for use as potential therapies (26, 73). In Wallace et al., 
Figure 1.1. Metabolism of CPT-11. Figure is adapted from (74). 
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utilizing a high-throughput screen of a compound library, they identified potent inhibitors of E. coli β-
glucuronidase (EcβG) (74). They showed that the inhibitors displayed sub-micromolar inhibition in vitro, 
as well as in cultured E. coli and anaerobic bacteria. Wallace et al. demonstrated that the inhibitors had no 
effect on mammalian β-glucuronidase and did not affect the viability of cultured bacterial or mammalian 
cells. This relationship was supported through crystallographic analysis of lead inhibitors bound to EcβG. 
Crystal structures of Inhibitors 2 and 3 in complex provided evidence that these structurally similar hits 
bind adjacent to the enzyme’s dynamic active site, which consists of residues Glu-413 and Glu-504 as 
well as the “bacterial loop,” a region of 17 amino acids at the solvent-exposed mouth of the active site 
that is not present in orthologous mammalian β-glucuronidase enzymes (Figure 1.2). By using a mutant 
form of EcβG where the “bacterial loop” is deleted, they showed that Inhibitors 1 and 4 bind at the active 
site along with Inhibitors 2 and 3.  Oral administration of one lead, when given to mice, was protective 
against CPT-11-induced diarrhea (Figure 1.3). Healthy 6- to 8-week old Balb/cJ mice that received 10 µg 
Inhibitor 1 orally in conjunction with CPT-11 exhibited significantly less diarrhea compared to mice that 
were given only CPT-11. They also displayed fewer histologic indicators of colonic toxicity, indicating 
that bacterial β-glucuronidase inhibition is able to protect the endothelial cells in the mouse GI tract 
against CPT-11-induced toxicity (74).  
 
 
 
Figure 1.2. Overlay of the x-ray crystallographic structures of human β-glucuronidase and 
EcβG bound to Inhibitor 2. Figure is adapted from (74). 
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1.9 NSAIDs  
Many classes of drugs that contain carboxylic acid or phenolic moieties (e.g., non-steroidal anti-
inflammatory drugs (NSAIDs), statins, anticonvulsants, and diuretics) are similarly inactivated and 
eliminated through the formation of acyl glucuronide metabolites. NSAIDs are notably associated with GI 
toxicity, often through unknown mechanisms (75–77). Owing to their success at relieving inflammation 
and pain, NSAIDs are among the most widely prescribed medications in the world with an estimated 5-
10% of the US population taking NSAIDs on a regular basis (32). Side effects from NSAID use can range 
from ulcers, stomach erosions, and submucosal hemorrhages, to life-threatening events such as bleeding 
and perforation (75, 78). GI complications from chronic NSAID use in the US have been estimated to 
cause as high as 100,000 hospitalizations and 16,500 deaths per year (79). The average risk of developing 
complications is up to five-fold greater in NSAID users as opposed to non-users (75, 80). 
Although the NSAID associated toxicities in the large intestine are well appreciated and 
understood, Graham et al. showed that 15 of 21 patients that were chronic NSAID users had evidence of 
small intestinal injuries (enteropathy), five of which had major erosions or multiple ulcers, compared to 
only 2 of 20 control patients (81). The mechanism underlying the enteropathy is less well understood. 
More recent advances in technology, namely video capsule endoscopy, have shown the extent of NSAID 
Figure 1.3. CPT-11-induced toxicity in mice is alleviated by pretreatment with Inhibitor 1. Figure is 
adapted from (74).Figure is adapted from (74). 
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related damage is wider than previously thought. Indeed two-thirds of patients have shown some form, 
either mild or severe, of drug-induced lesions in the small-intestine, holding true both for chronic use (> 3 
months) and for short-term use (< 1 week) (82).  
 
1.10 Alleviation of NSAID-induced toxicity 
 The mechanism underlying the development of NSAID-induced enteropathy has not been well-
established. Specifically, many NSAIDs contain a carboxylic acid moiety that is conjugated in the liver to 
glucuronic acid during a typical Phase II detoxification reaction (76, 83). These glucuronidated 
conjugates (acyl glucuronides) are then trafficked through the bile for excretion through the waste. Initial 
experiments indicated that NSAID acyl glucuronide metabolites are reactive with proteins affected during 
enteropathy, forming irreversible protein adducts (76, 83, 84), but direct evidence for the mechanism of 
the underlying cause remained elusive.  
With the discovery of selective bacterial β-glucuronidase inhibitors from Wallace et al., the lab of 
Dr. Urs Boelsterli (University of Connecticut) embarked on an investigation to use this system of 
inhibition to flush out the relative roles played by the NSAID acyl glucuronide metabolites and their 
aglycone parent molecules in the development of enteropathy. Indeed, using a study of diclofenac-
induced small intestinal ulcers, Loguidice et al. showed that selective inhibition of bacterial β-
glucuronidase alleviates the drug-induced toxicity, implicating the local accumulation of the parent 
aglycone molecule over the acyl glucuronide metabolite in the development of enteropathy (Figure 1.4) 
(85). This finding was reinforced in Saitta et al. where the researchers used analogous models of 
indomethacin- and ketoprofen-induced toxicity that was similarly relieved via β-glucuronidase inhibitors 
(Figure 1.5) and extended their findings by demonstrating that pretreatment with β-glucuronidase 
inhibitors does not affect the plasma pharmacokinetic profile of any of the above NSAIDs (86).  
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These results, along with advancing understanding of the interplay between mammalian host and 
symbiotic microbiota, allow for new and innovative drugs that target the microbiome in order to produce 
a therapeutic effect for the host (87). This system of enzyme-specific inhibition could be utilized to not 
only lessen acyl glucuronide-mediated toxicity, but also probe the pharmacodynamics of compounds that 
are similarly glucuronidated and recirculated in vivo. It may prove a critical step in drug development, 
especially those that are limited by toxic side effects. 
Figure 1.4. Macroscopic view of mouse jejunum in a model of diclofenac-induced ulceration. 
Large ulcers (DCF, black arrow) are extensive in mice treated with diclofenac. Ulcers appear blue 
following staining with nitroblue tetrazolium. After pretreatment with Inhibitor 1 (DCF + 
Inhibitor-1), only a single small ulcer is present (white arrow). Figure is adapted from (85). 
Figure 1.5. Indomethacin-induced ulcers (IND, white arrow) stained blue by nitroblue 
tetrazolium in the mouse jejunum. Treatment with Inhibitor 1 (Inh-1 + IND) protects mice from 
ulcerations. Figure is adapted from (86). 
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Chapter 2 
Extension of the Understanding of β-Glucuronidase from GI Bacteria and the Characterization of 
Novel Inhibitors
1
 
 
2.1 Summary 
 Bacterial β-glucuronidase plays an important role in drug-induced toxicity in the gastrointestinal 
tract.  Selective disruption of bacterial β-glucuronidases by small molecule inhibitors alleviates side 
effects of drug metabolites, which can be dose-limiting.  Here, we characterize putative β-glucuronidase 
inhibitors that impact β-glucuronidase activity in E. coli cells with EC50 values as low as 300 nM, but 
encouragingly prove ineffective in assays with purified mammalian β-glucuronidase. The 2.8 Å resolution 
crystal structure of one inhibitor bound to E. coli β-glucuronidase demonstrates that it contacts and orders 
a portion of the “bacterial loop” present in microbial, but not mammalian, β-glucuronidases.  We 
additionally express and purify β-glucuronidase enzymes from GI-associated species Streptococcus 
agalactiae and Clostridium perfringens and demonstrate that not all of the compounds are effective 
against each species.  Crystal structures of each new species highlight structural similarities and 
differences to the previously determined structure of E. coli β-glucuronidase. The most potent compound 
examined in this group was found to protect mice against CPT-11-induced diarrhea. These data advance 
the understanding of the chemical and structural basis of selective microbial β-glucuronidase inhibition, 
which may improve human drug efficacy and toxicity. 
  
                                                 
1
Adapted from: Roberts AB, et al. Molecular Insights into Microbial β-Glucuronidase Inhibition to Abrogate CPT-
11 Toxicity. Mol. Pharmacol. 2013 
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2.2 Introduction 
CPT-11, approved for use in a variety of malignancies and in preclinical trials for many more, is 
often limited by toxic gastrointestinal (GI) side effects (37–44). Similar GI complications from chronic 
use of non-steroidal anti-inflammatory drugs (NSAID), one of the most commonly prescribed 
medications worldwide, are of growing concern (77, 81, 82). Prescribed for diverse reasons, these drugs 
share a common metabolic pathway. CPT-11 and certain NSAIDs undergo conjugation with glucuronic 
acid (58, 76, 88, 89). In each case, these detoxified metabolites are reactivated in the intestinal lumen by a 
symbiotic bacterial enzyme, β-glucuronidase, leading to toxic damage to the intestinal epithelium (90).  
The role played by microbial enzymes in therapeutic metabolism has been appreciated since the 
early days of drug discovery (33).  We recently hypothesized that selective inhibitors would alleviate 
drug-induced toxicity mediated by bacterial β-glucuronidases. In vitro and cell-based assays demonstrated 
that a set of chemically similar compounds identified by high-throughput screening displayed potent, 
selective inhibition of E. coli β-glucuronidase (EcβG) and did not impact the viability of cultured 
bacterial or mammalian cells (74). Accordingly, oral administration of one of the inhibitors in mice 
alleviated CPT-11-induced diarrhea and intestinal damage (74). Furthermore, in a subsequent study, the 
administration of the same inhibitor protected mice from small intestinal ulceration caused by the 
NSAIDs diclofenac, indomethacin, and ketoprofen, which are also subject to glucuronidation and 
reactivation in the intestinal lumen (85, 86).   
Here we describe the inhibitory profile of four novel compounds that are chemically distinct from 
the originally reported set (74, 91), shown to be in vitro inhibitors of EcβG and non-lethal to cultured E. 
coli and mammalian cells. However, E. coli, from the Proteobacteria phylum, is only one of a myriad of 
species of bacteria that are known to populate the human GI tract. As such, we additionally expressed and 
purified β-glucuronidases from Streptococcus agalactiae and Clostridium perfringens, two Firmicute 
bacteria from the mammalian microbiota population. These enzymes were characterized kinetically, and 
four novel compounds were tested for their ability to impact enzyme activity. Interestingly, although each 
inhibitor was effective against EcβG, not all of the compounds were effective against S. agalactiae and C. 
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perfringens β-glucuronidase (SaβG and CpβG, respectively). The x-ray crystal structure of EcβG in 
complex with one of the inhibitors reveals that it binds to the entrance of the enzyme’s active site and 
makes contact with, but does not completely order, the flexible “bacterial loop” unique to the microbial β-
glucuronidases. This structure highlights the binding mode for one compound that was ineffective against 
SaβG and CpβG. By comparing that structure to the un-liganded structures of SaβG and CpβG, we can 
begin to draw conclusions as to why that particular compound is ineffective. We also show that the most 
potent of these new compounds protects mice from CPT-11-induced diarrhea. Taken together, these data 
enhance the understanding of the selective modulation of microbial β-glucuronidases, which may lead to 
the targeted alleviation of drug-induced toxicity in the human GI tract. 
 
2.3 Materials and Methods 
Expression and Purification 
E coli β-glucuronidase (EcβG) (EC 3.2.1.31) was expressed and purified as described previously 
(74). S. agalactiae and C. perfringens β-glucuronidase (SaβG and CpβG, respectively) were purified in an 
analogous manner with the addition of 0.5 mM TCEP to the buffers. Purified β-glucuronidase was stored 
in 20 mM HEPES, 50 mM NaCl, pH 7.4 at ~10 mg/mL at 
-
80 
oC.  The  Δ360-376 form of EcβG was 
created using PCR mutagenesis, confirmed by sequencing, and purified as described previously (74).   
Inhibitor Compounds 
Compounds identified from high-throughput screening (74, 91) were purchased from ASINEX, 
Inc, Moscow, Russia. Each compound was provided as a solid powder and dissolved initially in 100% 
DMSO at 25 mM. 
Kinetic and Equilibrium Inhibition Assays 
Inhibition assays were conducted by measuring the β-glucuronidase-catalyzed conversion of p-
nitrophenyl β-D-glucuronide (PNPG) to p-nitrophenol (PNP). PNPG was acquired from Sigma-Aldrich, 
St. Louis, MO, and stored by dissolving in water at 250 mM. The conversion of increasing concentrations 
of PNPG to PNP, in the presence of 10 nM enzyme, was measured in the presence of increasing 
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concentrations of putative inhibitors; zero-substrate and zero-inhibitor controls were carried out at the 
same time. Reactions were conducted in 96-well, clear-bottom assay plates (Costar, Tewksbury, MA) at 
37 
o
C in 50 µL of total volume. The reaction consisted of 10 µL of assay buffer (5% DMSO and 500 mM 
HEPES, pH 7.4), 5 µL of inhibitor (various concentrations), 5 µL of 100 nM enzyme, and 30 µL of 
substrate (various concentrations).  Product formation was calculated by measuring the change in 
absorbance over time at 410 nm using a PHERAstar Plus microplate reader (BMG Labtech, Ortenberg, 
Germany). The acquired data were analyzed using Microsoft Excel and Sigmaplot 11.0. From these data, 
Ki values were calculated for each of the compounds.  
A related assay was employed to calculate the IC50 values in the following manner. An analogous 
50 µL reaction, consisting of enzyme (1 nM final), buffer, PNPG (1 mM final), and variable 
concentrations of the inhibitors, was incubated at 37 
o
C for 6 hours to allow the reaction to reach 
equilibrium and then quenched with 100 µL 0.2 M sodium carbonate. The percent inhibition for each 
concentration of inhibitor was calculated based on changes in absorbance and used to plot a dose-
response curve. The IC50 value was calculated as the concentration of inhibitor that produced 50% in vitro 
inhibition.  The same assay was performed with purified bovine liver β-glucuronidase with PNPG as the 
substrate. 
We also tested the ability of these compounds to inhibit β-glucuronidase in E. coli cells. We grew 
HB101 E. coli cells, transformed with the pET-28a vector containing the β-glucuronidase gene, to an 
OD600 of 0.6 in LB medium and used a small aliquot in an assay similar to the in vitro IC50 assay 
described above. The cells (39 µL) were incubated with 1 µL of variable concentrations of inhibitor and 
10 µL of 1 mM PNPG at 37 
o
C for 6 hours. The reaction was quenched with 100 µL 0.2 M sodium 
carbonate. The amount of substrate turnover and therefore the amount of inhibition is calculated from the 
change in absorbance compared to zero-inhibitor controls. EC50 values were calculated as the amount of 
inhibitor necessary to produce 50% inhibition.  The in vitro and cell-based assays employed here were 
similar to those reported previously (74). 
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Additional Glycosidase Enzymes 
Mammalian (bovine liver) β-glucuronidase (lyophilized powder, EC 3.2.1.31), Prunis dulcis β-
glucosidase (lyophilized powder, EC 3.2.1.21), Helix pomatia β-mannosidase (ammonium sulfate 
suspension, EC 3.2.1.25), E. coli β-galactosidase (lyophilized powder, EC 3.2.1.23), and bovine liver β-
galactosidase (lyophilized powder, EC 3.2.1.23) were purchased from Sigma-Aldrich, St. Louis, MO. The 
assays were conducted as previously published, using the appropriate p-nitrophenyl-glycosidase 
compound as the primary substrate for enzyme activity detection (92). Each of the four inhibitors was 
tested for an effect on each glycosidase enzyme activity by adding a concentration range of 0 to 100 µM 
to the reaction mixture. The reaction was allowed to proceed for 6 hours at 37 
o
C and then quenched with 
100 µL 0.2 M sodium carbonate. Absorbance was measured at the appropriate wavelength, and the data 
were analyzed using Microsoft Excel and SigmaPlot 11.0. 
Toxicity of Inhibitors Toward Cultured Cells 
The toxicity of inhibitors to bacterial cells was examined by incubating HB101 E. coli cells, 
transformed with the pET-28a vector containing the β-glucuronidase gene,  grown to an OD600 of 0.6 in 
LB medium with each compound, as well as DMSO and ampicillin as controls, for 6 hours. Cell 
survivability was measured by plating a 10
-5
 dilution of the cells on LB media enriched with kanamycin. 
After overnight incubation, colonies were counted to quantify cell viability.  We used a similar assay to 
assess the inhibitor’s toxicity toward cultured HCT116 human colon cancer cells, which were grown and 
cultured in DMEM media. Aliquots of HCT116 cells were incubated with 100 µM of each lead for 24 
hours. The resulting viability of the cells was quantified by using the CellQuanti-Blue™ Cell Viability 
Assay Kit (BioAssay Systems, Hayward, CA). Cells are incubated with CellQuanti-Blue™ Reagent and 
fluorescence was measured. 
Crystal Structure Determination 
Crystals of EcβG were obtained at 2 mg/mL protein with 30-fold molar excess Inhibitor 8 
(Figure 2.1) in 17% PEG-3350 (w/v), 250 mM magnesium acetate, and 0.02% sodium azide (w/v) at 16 
°C. Crystals first appeared after 5 days and were immediately cryo-protected with perfluoropolyether 
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vacuum pump oil (Sigma-Aldrich, St. Louis, MO) and flash-cooled in liquid nitrogen. Diffraction data 
were collected on the 22-BM beam line at SER-CAT (Advanced Photon Source, Argonne National 
Laboratory). Data in space group C2 were indexed and scaled using HKL2000 (93) to 2.83 Å resolution. 
The asymmetric unit contained two monomers. The structure was determined with Phaser (94) using 
molecular replacement with the recent apo EcβG structure (PDB ID 3K46) as a search model. The 
structure was refined using simulated annealing and torsion angle refinement with the maximum 
likelihood function target in CNS, and monitored using both the crystallographic R and cross-validating 
R-free statistics (95). The software suite PHENIX (96) was also employed for grouped B-factor (with two 
groups – main chain, and side chain) and TLS refinement. The model was manually adjusted using Coot 
(97) and 2Fo-Fc and Fo-Fc electron density maps. The ligand model and definition files were generated 
using PRODRG (98), and were placed into electron density in the active site of both monomers in the 
asymmetric unit. 
Animal Studies 
Animal experiments were performed according to the Institutional Animal Care and Use 
guidelines approved by the Institutional Animal Care and Use Committee (IACUC # 20070715 and 
20100711) of the Albert Einstein College of Medicine, Bronx, New York. This work was conducted by 
our collaborator, Dr. Sridhar Mani (Albert Einstein College of Medicine). CPT-11 was purchased from 
LC Laboratories, Woburn, MA (catalog number: I-4122) as a hydrochloride salt (> 99% HPLC purified 
grade). CPT-11 (20 mg/mL) and Inhibitor 5 (100 μg/mL) were dissolved in 0.25% (w/v) 
carboxymethylcellulose sodium salt (Sigma, C5013) to make stock solutions.  As a vehicle control, all 
animals received an equivalent volume (compared to experimental groups) of 0.25% (w/v) 
carboxymethylcellulose sodium salt solution. BALB/cJ female mice (8-10 week old) were obtained from 
Jackson Laboratories, Bar Harbor, ME. The mice were housed in conventional metabolic cages 
(N=1/cage) and kept in a room under controlled temperature (20-22 
o
C) and 12 hour day-night cycle. 
Animals had free access to water and conventional food without fortification. Mice were divided into four 
groups of 9 animals each: Group 1, vehicle controls received equivalent volume of 0.25% (w/v) 
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carboxymethylcellulose sodium salt solution intraperitoneally (i.p.) and by oral gavage (~100 µL twice 
per day); Group 2, Inhibitor 5 gavaged (10 µg/day) twice per day (every 10 hours) starting on day 
–
1 with 
oral gavage of 0.25% (w/v) carboxymethylcellulose sodium salt solution, and i.p. once per day; Group 3, 
CPT-11 injected (50 mg/kg) i.p. once daily in the morning with oral gavage of 0.25% (w/v) 
carboxymethylcellulose sodium salt solution; Group 4, CPT-11 injected (50mg/kg) i.p. once daily in the 
morning, and Inhibitor 5 gavaged (10 µg/day) twice per day (every 10 hours). Total injected volume was 
identical for each animal. Mice were weighed and examined daily for signs of diarrhea (fecal staining of 
skin, lose watery stool) and bloody diarrhea (black sticky stool). Body weight, stool consistency and 
blood in stool were monitored daily using methods previously published (74, 99).  Previous studies 
indicate that dosing at ~60-80 mg/kg/day of CPT-11 for 4 days allows for observation of delayed diarrhea 
around 15 days (100). A dosing scheme of 50 mg/kg/day, once daily for 9 days, was chosen with the 
intention of accelerating the onset of diarrhea while preventing death. As outlined previously, 50 mg/kg 
CPT-11 in mice is roughly equivalent to the 5 mg/kg typical human CPT- 11 dose based on differences in 
body surface area (63, 100). GI symptoms in Group 3 started as early as day 2 and up to day 10, and 
included decreased appetite, bowel movements, mobility and body weight. All animals were euthanized 
on day 11.  
 
2.4 Results 
2.4.1 In vitro and Cell-Based E. coli β-Glucuronidase Inhibition 
Eight compounds (Inhibitors 1-8) were chosen from high-throughput screening results (74, 91) 
for further functional and structural characterization (Figure 2.1).  Inhibitors 5-8 are relatively distinct in 
structure from one another and are also distinct from the four chemically-similar compounds (Inhibitors 
1-4) reported previously (74).  In in vitro assays with purified E. coli β-glucuronidase (EcβG) using the 
substrate p-nitrophenyl glucuronide (PNPG), we found that all four compounds functioned as inhibitors, 
with IC50 and Ki values ranging from 180 nM (Inhibitor 5) to 15 µM (Inhibitor 7) (Table 2.1), similar to 
those observed previously with Inhibitors 1-4 (74). Inhibitors 5, 6 and 8 were effective against the β-
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glucuronidase target in living E. coli cells. Only Inhibitor 7, the weakest in vitro compound, showed no 
impact in cells, while Inhibitors 5, 6, and 8 exhibited 310 nM, 750 nM, and 1.2 µM EC50 values, 
respectively (Table 2.1).  The relatively potent in-cell EC50 values compared to the in vitro IC50 values 
are likely due to differences in compound entry, metabolism, export, or partitioning within living cells; 
such features will be examined in future studies.   
   
 
 
 
 
2.4.2 C. perfringens and S. agalactiae β-Glucuronidase Activity and Inhibition 
 While EcβG, the original target for screening for inhibitors, has been examined in vitro both 
structurally and with inhibitors, we now sought to examine β-glucuronidases obtained from other human 
GI-associated microbial species. Thus, the β-glucuronidases from Clostridium perfringens and 
Streptococcus agalactiae (CpβG and SaβG, respectively) were cloned, overexpressed and purified. While 
E. coli is part of the Proteobacteria phylum, these species belong to the Firmicute phylum, a major source 
of GI β-glucuronidase activity in humans.  
Figure 2.1. Chemical structures of A) Inhibitors 1-4, which share a common scaffold, and B) 
Inhibitors 5-8. 
 
Table 2.1. In vitro and cell-based assays for β-glucuronidase activity and inhibitor efficacy. Errors 
represent SEM, where N = 3. NI, no inhibition 
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They were initially assayed in vitro to determine their kinetic parameters, and those values were 
compared to EcβG (Table 2.2).  The kcat values for EcβG and SaβG were found to be similar, at 40 and 24 
sec
-1
, respectively, while CpβG exhibited a 10-fold slower turnover (kcat = 2.6 sec
-1
).  Furthermore, SaβG 
and CpβG were both found to have reduced binding affinities for PNPG relative to EcβG, exhibiting low-
millimolar for CpβG (KM = 1.1 mM) to micromolar for SaβG (KM = 350 µM), while EcβG demonstrated 
a low-micromolar (KM = 160 µM) affinity.  Thus, these three enzymes exhibit nearly a 100-fold 
difference in catalytic efficiency (kcat/KM), with EcβG the best at 260 sec
-1
mM
-1
 (Table 2.2). Despite the 
reasonable sequence similarity between the enzymes (42-47% identity), their activities toward a 
glucuronidated substrate varies nearly two orders of magnitude.
 
 
 
We next examined SaβG and CpβG in kinetic assays with Inhibitors 1-8 (Table 2.3, Figure 2.1).  
Inhibitors 5-8, which are not related to each other or to Inhibitors 1-4 in chemical structure (Figure 2.1B), 
exhibited more variability, including Inhibitor 7 and Inhibitor 8 that proved ineffective against these new 
species.  Inhibitor 5 is the most potent exhibiting Ki values for SaβG and CpβG in the mid-nanomolar 
range (540 and 810 nM, respectively).  Inhibitor 1 produced similar potency against SaβG and CpβG (Ki 
= 970 nM and Ki = 1400 nM, respectively).  Interestingly, Inhibitor 7, which was effective at disrupting 
EcβG (Ki = 1.9 µM), did not inhibit SaβG and CpβG. Similarly, Inhibitor 8 (Ki = 960 nM against EcβG) 
did not inhibit CpβG and only produced 30% inhibition at 100 µM with SaβG (estimated Ki = 20 µM) 
(Table 2.3). Thus, while Inhibitors 1-6 demonstrated efficacy against the three microbial β-
Table 2.2. Kinetic data were estimated by non-linear fitting using p-nitrophenyl glucuronide as the 
substrate. 
a 
N = 6 ± SEM; 
b 
N = 3 ± SEM 
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glucuronidases purified to date (EcβG, SaβG and CpβG), Inhibitors 7 and 8 indicate that certain chemical 
scaffolds will exhibit selectivity toward specific β-glucuronidase orthologues. 
 
 
 
2.4.3 Selectivity for Bacterial β-Glucuronidase 
We next tested the ability of Inhibitors 5-8 to disrupt the activity of purified β-glucuronidase from 
bovine liver, a mammalian enzyme orthologue.  We found that Inhibitors 5-8 were ineffective at 
concentrations up to 100 µM (Figure 2.2). These same results were previously seen for Inhibitors 1-4 
(74). Using the appropriate substrate, we additionally probed the in vitro effects of these compounds on 
related glycoside hydrolases, which included four commercially-available enzymes: a plant β-glucosidase 
(from the almond tree Prunis dulcis), a mollusk β-mannosidase (from Helix pomatia), and β-
galactosidases from E. coli and bovine sources.  In all cases, Inhibitors 1-8 failed to exhibit inhibition at 
compound concentrations up to 100 µM (data not shown).  Thus, we conclude that the β-glucuronidase 
inhibitors, Inhibitors 1-8, do not inhibit either mammalian β-glucuronidase or members of the related 
family of sugar-cleaving enzymes from a range of sources, demonstrating selectivity.    
Table 2.3. Enzyme inhibition properties of small molecule inhibitors against representative β-
glucuronidase enzymes from the mammalian microbiome. Data are presented as the average (N > 3) ± 
SEM. NI: no inhibition.  
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2.4.4 Lethality to Bacterial and Mammalian Cells 
 Disruption of GI-associated microbial β-glucuronidases in order to eliminate toxic drug 
metabolites but maintain proper physiology requires that compounds are not toxic.  Therefore, we tested 
the potential lethality of Inhibitors 5-8 to cultured E. coli or HCT116 human colon cancer cells at 
compound concentrations up to 100 µM.  We found that all four inhibitors did not affect the survival of 
either E. coli or HCT116 cells (Figure 2.3).  Thus, they appear to satisfy the criteria that successful 
compounds are relatively non-toxic to bacterial or human epithelial cells. 
 
 
 
Figure 2.2. Impact of increasing concentrations of Inhibitors 5-8 on the activity of a representative 
mammalian β-glucuronidase. 
 
 
Figure 2.3. Impact of Inhibitors 5-8 at 100 µM on the survival of E. coli (A) and HCT116 cells (B).  
Ampicillin and 10% Triton-X100 are used as positive controls for microbial and human cell lethality, 
respectively. DMSO, in which the inhibitors are solubilized, is also shown. 
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2.4.5 Structure of EcβG in Complex with Inhibitor 8 
 To further the understanding of the molecular basis of EcβG inhibition, we determined the 2.8 Å 
resolution crystal structure of the enzyme in complex with Inhibitor 8 (PDB ID 4JHZ) (Table 2.4). The 
asymmetric unit contained two β-glucuronidase monomers (Figure 2.4A), while C2 crystallographic 
symmetry produced the physiologically relevant β-glucuronidase tetramer (74).  The apo (unliganded) 
structure of EcβG was used as a molecular replacement search model to eliminate any previous ligand 
model bias. After careful refinement of the protein structure, electron density at 1.0 σ level in the 
composite omit map was present for Inhibitor 8 in both monomers of the asymmetric unit (Figure 2.4B). 
After refinement of the atomic positions as well as their thermal displacement parameters (B-factors), the 
ligands had an occupancy of 0.93 and 0.91 with an average B-factors of 66.4 Å
2
 and 76.5 Å
2
 for chain A 
and B, respectively.  
 
 Table 2.4. Crystallographic Statistics of full-length EcβG in complex with Inhibitor 8. 
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Inhibitor 8 was placed in an orientation that both satisfies the electron density and makes 
chemically reasonable interactions with the neighboring amino acid side chains.  It binds to the entrance 
to the active site cleft (Figure 2.4A), contacting Asp-163, Val-446, Phe-448, Tyr-472, and Arg-562 
within the active site region of the enzyme and 3.5 Å from the catalytic residue Glu-413 residue (Figure 
2.5).  Notably, in chain A  it directly contacts Leu-361 of the “bacterial loop,” a region that is unique to 
the microbial forms of the β-glucuronidase relative to the mammalian β-glucuronidases (74, 101). 
Inhibitor 8 binds in a similar manner to Inhibitors 2 and 3 described previously in complexes with EcβG 
(74), occupying a similar location in the enzyme and contacting 5 of the same residues (Figure 2.5).  
Indeed, the root-mean-square deviation between the Cα positions of the Inhibitor 2- and Inhibitor 8-bound 
structures of EcβG is 0.54 Å.  However, while most residues contacted by Inhibitor 8 are in the same 
position in the Inhibitor 2 complex structure, the side chain of Leu-361 shifts by 3.6 Å. This observation 
suggests that the “bacterial loop” is capable of conforming to the presence of different bound ligands. 
Electron density in the simulated annealing omit and 2Fo-Fc maps is less complete for Leu-361 in chain B 
compared to chain A.  
Figure 2.4. A.  Crystal structure of the EcβG dimer in complex with Inhibitor 8 (PDB ID 4JHZ).  
B. Composite annealing omit (σA-weighted) 2.8 Å resolution electron density contoured at 1.0 σ 
for Inhibitor 8 in the active site of each monomer of EcβG.   
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The full “bacterial loop” of EcβG, residues 360-376, was visualized in the Inhibitor 2 and 3 co-
crystal structures (74); in complex with Inhibitor 8, though, only residues 372-376 are ordered with 
average B-factors less than 80 Å
2
 (Figure 2.6A).  In the absence of a bound ligand, the “bacterial loop” is 
not observed, as it gave no interpretable electron density in the structure of apo EcβG reported previously 
(74). Thus, we conclude that EcβG can be inhibited effectively by compounds, like Inhibitor 8, capable of 
contacting a portion of the loop unique to the microbial β-glucuronidases. In support of this conclusion, 
we found that a form of EcβG in which the “bacterial loop” was deleted, Δ360-376, was not inhibited by 
up to 100 µM of Inhibitors 5-8 (Figure 2.6B). The Δ360-376 EcβG exhibited comparable KM (260 µM 
for Δ360-376, 360 µM for wild-type) values, but the kcat (0.24 sec
-1
 for Δ360-376, 40 sec-1 for wild-type) 
values were reduced by 2 orders of magnitude. Thus, the “bacterial loop” is essential for full activity of 
EcβG, as well as its selective inhibition.  
  
Figure 2.5. Contacts formed by Inhibitor 8 (pink) at the active site of EcβG.  Inhibitor 2 (yellow) 
from a previously resolved structure is also shown, as are the side chains for the Inhibitor 8 and 
Inhibitor 2 complexes (blue and purple, respectively). 
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2.4.6 Structural Comparison of SaβG and CpβG to EcβG in Complex with Inhibitor 8 
Overlaying the structure of EcβG in complex with Inhibitor 8 with un-liganded CpβG, steric 
clashes appear from residues in CpβG against the Inhibitor 8 binding site (Figure 2.7A). A slight clash is 
created by the CpβG active site residue Leu-447, but a much larger clash can be seen from Met-364, part 
of the “bacterial loop”. Overlaying the SaβG P21212 structure (Figure 2.7B), steric clashes between 
Inhibitor 8 and Met-444 and Leu-443 residues are seen. In the SaβG I222 structure (Figure 2.7B), 
however, there is a slight clash between Inhibitor 8 and residue Met-444, but Leu-443 is in a slightly 
different conformation that eliminates the clash seen in the SaβG P21212 structure. This discrepancy 
between the two SaβG structures provides a potential mechanism for the partial inhibition of Inhibitor 8 
against purified SaβG.  
  
Figure 2.6. A. Bound Inhibitor 8 (pink) adjacent to the largely disordered “bacterial loop” of EcβG 
(blue). The completely ordered “bacterial loop” of EcβG (purple) in complex with Inhibitor 2 
(yellow) is overlaid for comparison. The image is in the same orientation as Figure 5 B. Inhibitors 5-
8 at 100 µM inhibit wild-type (WT) EcβG, but not a mutant EcβG in which the “bacterial loop” 
(residues 360-376) has been deleted. 
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Although the active sites of the CpβG and SaβG structures are unchanged with respect to 
published EcβG-bound structures, the binding site for Inhibitors 5-8 are more divergent. Figure 2.8 
depicts the active site residues directly surround the bound Inhibitor 8 in the EcβG structure. A structural 
alignment of the CpβG and two SaβG structures reveals both similarities and differences in amino acid 
composition and side chain conformations surrounding Inhibitor 8. Conserved residues in CpβG include 
the active site residues Glu-413 and Glu-504, as well as the additional residues Asp-164, Thr-557, Ser-
558, Arg-563, Tyr-468, Val-473, and Tyr-472. Similar to the E. coli structure, Ile-562, Met-364, Leu-447, 
and Met-448 provide hydrophobic contacts. The SaβG inhibitor binding site also consists of Asp-160, 
Thr-553, Arg-559, Leu-558, Tyr-468, Val-469, Tyr-464, and the catalytic residues Glu-413 and Glu-504, 
all of which are conserved in the EcβG enzyme for bound inhibitors.  
Figure 2.7. (A) Aligned structures of EcβG Inhibitor 8-bound (Inh8) structure with CpβG 
highlighting the “bacterial loop” region. Key residues adjacent to the inhibitor binding site are 
displayed. Steric clashes between key residues in the CpβG structure and the bound Inhibitor 8 
molecule from the EcβG structure are emphasized with spheres. (B) Aligned structures of EcβG 
Inhibitor 8-bound structure with the two SaβG crystal structures. Key residues adjacent to the 
inhibitor binding site are displayed. Steric clashes between key residues in the two SaβG structures 
and the bound Inhibitor 8 molecule from the EcβG structure are emphasized with spheres. 
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 A number of differences in the environment surrounding the inhibitor binding site are observed 
when comparing the EcβG to the CpβG and SaβG structures (Figures 2.8). Surrounding the 1,3-
benzodioxol moiety for Inhibitor 8, CpβG and SaβG have a phenylalanine (Phe-163 and Phe-159) in 
place of His-162 in the EcβG enzyme. Furthermore, the SaβG enzyme has Asn-554 in two conformations, 
replacing the Ser-557 and Ser-558 found in the EcβG and CpβG structures, respectively. Encompassing 
the 2,5-dimethoxycyclohexyl moiety for Inhibitor 8, the CpβG enzyme has Tyr-446 and Phe-363 that 
replace Val-446 and Ser-460 in EcβG. Side-chain conformations of residues in the SaβG and CpβG 
structures that do not align well with the EcβG residues detail areas that may limit strong inhibitor 
binding. 
2.4.7 Alleviation of CPT-11 Toxicity in Mice 
 We tested the ability of the most potent compound examined in this study, Inhibitor 5 (Ki = 180 
nM, EC50 = 300 nM), to alleviate CPT-11-induced intestinal toxicity in mice. We divided BALB/cJ 
female mice into four groups of nine animals each. Group 1 received an equivalent volume of only the 
vehicle (0.25% (w/v) carboxymethylcellulose sodium salt solution) intraperitoneally (i.p.) and by oral 
Figure 2.8. Structural overlay of the β-glucuronidase structures reported here along with the active 
site of the Inhibitor 8-bound EcβG structure. Residues that interact on both sides of the Inhibitor 8 
molecule are predicted to be highly conserved spatially, and nearly identical as well. 
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gavage twice per day. Group 2 received an oral gavage of Inhibitor 5 (10 µg/day) twice per day starting 
on day 
–
1, as well as an i.p. injection of the vehicle solution once per day. Group 3 was injected with 
CPT-11 (50 mg/kg) i.p. once per day and received an oral gavage of the vehicle solution twice per day. 
Group 4 received both an injection of CPT-11 (50 mg/kg) once per day and an oral gavage of Inhibitor 5 
(10 µg/day) twice per day. The mice were observed and weighed daily, and were examined for incidence 
of diarrhea and bloody diarrhea (Figure 2.9). Groups 1 and 2 showed no evidence of toxicity throughout 
the experiment. In group 3, GI symptoms were observed as early as day 2 and incidences of bloody 
diarrhea were observed in a third of the mice at day 8, and in all animals by day 10. In comparison, in 
group 4, where the mice were pretreated with Inhibitor 5, no mice showed evidence of bloody diarrhea by 
day 8 and less than 30% of mice showed symptoms by day 10 (Figure 2.9A).  
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The body weight of each mouse was also recorded each day during the course of the experiment 
(Figure 2.9B). Although Inhibitor 5 alleviated most of the toxicity associated with the CPT-11 treatment, 
it had no effect on the average body weight of the mice. Moreover, group 2, which only received 
treatment with Inhibitor 5, showed comparable body weights to the vehicle-only group, but had 
significantly higher body weights, starting at day 6, than group 4, which received treatment with Inhibitor 
5 in addition to CPT-11. These data indicate that the presence of Inhibitor 5 significantly reduces the 
incidence of acute GI toxicity caused by CPT-11, and they suggest that Inhibitor 5 does not impact the 
systemic effects of this anticancer drug, as measured by weight loss. 
 
2.5 Discussion 
 Research endeavors like the Human Microbiome Project continue to expand the appreciation of 
the roles the symbiotic microbiota play in mammalian physiology (1). It also appears that widespread use 
of antibiotics may have subtle but serious side effects on human health (102). Additionally, for patients 
with colorectal cancer, the use of antibiotics to treat CPT-11-induced toxicity may lead to the increased 
prevalence of subdominant bacterial species with higher overall β-glucuronidase activity in the GI tract, 
Figure 2.9. A. Groups of nine BALB/cJ mice were dose with either vehicle, Inhibitor 5, CPT-11, or 
pre-treated with Inhibitor 5 followed by CPT-11, and then examined for incidences of CPT-11-
induced toxicity (i.e., bloody diarrhea). B.  The mice were weighed daily. Administration of CPT-11 
incited the loss of body weight during treatment. Oral administration of Inhibitor 5 had no protective 
effects on body weight during CPT-11 treatment. The Inhibitor 5 only and CPT-11 + Inhibitor 5 
groups were analyzed for statistical significance. **, p < 0.01 and ***, p < 0.001 
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and thus, increased toxicity (63). Studies have also shown that the long-term use of neomycin in mice 
leads to increased serum bilirubin that may interfere with proper hepatic CPT-11 metabolism (103). These 
observations lead to the conclusion that the selective, non-lethal inhibition of components of the GI 
microbiome will be an important method of enhancing drug efficacy and tolerance. In this report, we 
interrogate the roles bacterial β-glucuronidases play in mammalian GI drug toxicity by pharmacologically 
targeting this enzyme with potent and selective inhibitors.  
Inhibitors 5-8 exhibited strong in vitro inhibition of EcβG (Table 2.1) but did not affect the 
viability of either cultured bacterial or mammalian cells (Figure 2.3). Only Inhibitor 7 failed to disrupt β-
glucuronidase activity in living E. coli cells. Furthermore, because compounds were ineffective against 
mammalian β-glucuronidase (Figure 2.2) and a range of enzymes from the glycosidase family, each 
inhibitor displayed selectivity toward EcβG. The selectivity of the inhibitors is particularly critical 
because human β-glucuronidase expressed by tumor cells appears to play an important role in the anti-
tumor efficacy of CPT-11 through the reactivation of SN-38G to SN-38 in the tumor microenvironment 
(88, 104). Of Inhibitors 5-8, only Inhibitor 5 (Ki = 180 nM, IC50 = 540 nM) displayed potency comparable 
to previously-characterized inhibitors, which have a scaffold not shared by the four inhibitors outlined in 
this study (74).  
Because β-glucuronidase activity has been shown in a range of bacterial species, we purified β-
glucuronidases from Clostridium perfringens and Streptococcus agalactiae, symbiotic species known to 
populate the human GI tract. Moreover, these enzymes belong to a different phylum (Firmicute) than the 
orthologous EcβG protein (Proteobacteria), but share a 42-47% sequence identity and high degree of 
structural conservation. Kinetic analysis shows that CpβG and SaβG are slower enzymes than EcβG. 
SaβG has a 10-fold decrease in catalytic efficiency, while CpβG is 100-fold slower. Mutagenesis studies, 
likely focused on divergent residues in the “bacterial loop,” will be required to understand these observed 
differences in activity. Each of the eight inhibitors was additionally tested against these newly purified 
enzymes. Only Inhibitors 1 and 5 maintained potency, and Inhibitors 7 and 8 proved ineffective. As such, 
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these data advance the understanding of the chemical moieties capable of selective bacterial β-
glucuronidase inhibition.  
 Contributing to the mechanism of EcβG inhibition that includes the structures of the complexes 
of Inhibitors 2 and 3 reported previously (74), we successfully determined the x-ray crystal structure of 
one inhibitor (Inhibitor 8) in complex with EcβG (Figure 2.4). Similar to those structures, Inhibitor 8 
binds at the entrance to the active site cleft and forms related contacts, including one with the catalytic 
glutamic acid residue, Glu-413. Importantly, Inhibitor 8 also makes a hydrophobic contact with Leu-361, 
which is part of the “bacterial loop” unique to the microbial enzymes. Overlaying the structures of the 
complexes with Inhibitor 2 and Inhibitor 8, it is apparent that Leu-361 has shifted to facilitate binding, 
suggesting that “bacterial loop” flexibility is involved in inhibition (Figure 2.6). The observation that the 
“bacterial loop” in the Inhibitor 8 complex structure is disordered for the eight residues C-terminal to 
Leu-361 supports that conclusion.  Mutagenesis studies in which the “bacterial loop” has been deleted 
confirm its importance in microbial β-glucuronidase inhibition (Figure 2.6). 
Unlike Inhibitors 1-4, Inhibitors 5-8 do not share a common scaffold from which to draw 
conclusions about their mechanism of inhibition or non-inhibition. Using the x-ray crystal structure of 
EcβG in complex with Inhibitor 8, we can begin to draw conclusions as to why Inhibitor 8 is not an 
inhibitor for CpβG and only a partial inhibitor for SaβG. By overlaying the Inhibitor 8-bound EcβG 
structure with the CpβG and SaβG structures (Figure 2.7), we hypothesize that differences in the 
structure and conformation of active site residues in CpβG and SaβG obstruct binding of the Inhibitor 8 
molecule, and thus, prevent inhibition.  
Only the previously reported Inhibitor 1 had been examined to date in drug-induced GI toxicity 
studies in mice (74, 85).  In this report, we tested the in vivo efficacy of the most effective compound 
outlined here, Inhibitor 5, in a mouse model of CPT-11 toxicity (Figure 2.9). Groups of BALB/cJ mice 
were dosed with Inhibitor 5, CPT-11, or a combination of both. The group that received CPT-11 alone 
developed bloody diarrhea by day 8, and 100% of the mice showed signs of this toxicity by day 10. The 
group that was treated with Inhibitor 5 orally, along with CPT-11 by i.p., had significantly fewer incidents 
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of bloody diarrhea compared to the CPT-11 group, highlighting the protective effects of Inhibitor 5. It is 
also interesting to note that the mice that received CPT-11 lost body weight at the same rate regardless of 
treatment with Inhibitor 5. This suggests that Inhibitor 5 protects against CPT-11-induced GI toxicity, but 
the pharmacodynamics of CPT-11 in the mouse are not impacted.  A more comprehensive examination of 
tumor xenografts and pharmacokinetics will be required to substantiate this conclusion.  
 We have described the inhibitory profile of a range of chemically-distinct compounds and 
assessed their potential as orally delivered pharmacological agents. They are in vitro inhibitors with 
varied potencies to the tested bacterial β-glucuronidases and, with the exception of Inhibitor 7, are also 
effective in E. coli cells. Moreover, the inhibitors appear to be selective for bacterial β-glucuronidase and 
non-lethal to bacterial and mammalian cells. The structural data presented here, along with the data from 
previously-characterized inhibitors, will allow us to better understand their mechanism of selective 
microbial β-glucuronidase inhibition. As such, they may facilitate the development of therapeutics 
capable of alleviating drug-induced GI toxicity generated by symbiotic microbial β-glucuronidases. 
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Chapter 3 
Novel Inhibitors Designed Toward Altered Pharmacokinetic Properties Using Structural and 
Chemical Biology 
 
3.1 Summary 
 Prior work has demonstrated the ability and the utility in designing small-molecule inhibitors that 
target a symbiotic microbial enzyme for a therapeutic outcome. Certain drugs, most notably NSAIDs and 
the widely-used anti-cancer drug CPT-11, are hampered by gastrointestinal toxicities that limit the drugs’ 
efficacy and may potentially be fatal. In each case, a microbial enzyme, β-glucuronidase, has been 
implicated in mediating toxicities. Our lab has worked on developing selective, non-toxic inhibitors of β-
glucuronidase to alleviate these toxic side effects. We have demonstrated the utility of the system in 
models of CPT-11-induced diarrhea and in models of NSAID-induced intestinal injuries. Here, we 
continue the development of a potential therapeutic by rationally designing inhibitor analogues of a lead 
compound to decrease intestinal absorption and increase the amount of compound that reaches the 
intestinal microbiota.  The design successfully decreased the bioavailability of inhibitors in mice, but the 
analogues suffered from a loss of in vitro potency that led to a decrease in in vivo efficacy. Preliminary in 
vivo studies using xenografted tumors in mice indicate that the system of inhibition does not negatively 
affect the pharmacokinetic profile or the anti-tumor ability of CPT-11.Further work is needed to establish 
improved CPT-11 efficacy with reduced toxicity.  
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3.2 Introduction 
 Although the need to maintain a healthy microbiota is becoming increasingly appreciated, one 
area that the microbiota play a clear and direct role in a negative outcome for humans is drug-induced 
toxicity (32, 33, 63, 79). Xenobiotic compounds, ingested or otherwise administered, are typically 
detoxified in the liver, first through oxidation (Phase I), and then through conjugation (Phase II) with an 
often polar moiety. These inactive metabolites are then circulated through the bile system to be excreted. 
However, enzymes expressed by the host microbiota in the intestinal tract are able to reverse the 
detoxifying conjugation reaction, reactivating the parent drug, before the compounds are harmlessly 
excreted (82, 87). Although this reaction is beneficial in some cases through enterohepatic circulation and 
an increase in the amount of active drug in systemic circulation over a longer period of time, the reaction 
may also engender toxic side effects locally in the intestinal tract. Importantly, in combination with 
increasing appreciation of the interplay between microbiota and host metabolism, the key players present 
in the microbiome are, for the first time, viewed as drug targets for a therapeutic outcome for the host 
(90).  
 Although we have since begun to investigate additional models of drug-induced toxicity, work 
from our lab had first focused on the dose-limiting side effect of the anti-cancer drug, CPT-11. Given 
intravenously, CPT-11 is a prodrug for its active metabolite, SN-38, which is subsequently detoxified in 
the liver through conjugation with UDP-glucuronic acid, producing SN-38-glucuronide (SN-38G) (58). 
This inactive metabolite then acts a substrate for a microbial enzyme, known as β-glucuronidase, which 
hydrolyzes the glucuronide moiety as a source of carbon and reproduces the active metabolite, SN-38, 
into the intestinal lumen, which is then taken up into the intestinal epithelial cells, where it mediates cell 
damage and death (63, 105). Indeed, the same traits that make CPT-11 such an effective anti-cancer 
treatment also make it quite toxic to healthy cells.  
We have developed microbial-specific β-glucuronidase inhibitors (74, 106). Previous work has 
outlined the discovery and biochemical characterization of a group of putative inhibitors against β-
glucuronidases purified from GI-associated bacteria, but in this work, we seek to expand the 
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understanding of the in vivo effects of the inhibitors. We also outline initial attempts at developing 
chemical modifications to lead compounds in order increase their in vivo efficacy and the successes and 
pitfalls that came with those attempts. Lastly, we move forward with the lead compound into in vivo 
efficacy studies.  
 
3.3 Materials and Methods 
Reagents 
 The assay substrate p-nitrophenyl β-D-glucuronide (PNPG) and bovine liver β-glucuronidase 
were purchased from Sigma-Aldrich (St. Louis, MO). β-glucuronidase (EC 3.2.1.31) from E. coli, S. 
agalactiae, and C. perfringens (EcβG, SaβG, and CpβG, respectively) were expressed and purified as 
described previously (74). Purified β-glucuronidase was stored in 20 mM HEPES, 50 mM NaCl, pH 7.4 
at ~10 mg/mL at 
–
80 
o
C. Inhibitors 1-8 were synthesized by Asinex, Inc. (Winston-Salem, NC). Inhibitors 
were identified by high-throughput screening and secondary validation was performed in-house (37). 
Kinetic and Equilibrium Inhibition Assays.  
Inhibition assays were conducted by measuring the β-glucuronidase-catalyzed conversion of 
PNPG to p-nitrophenol (PNP). PNPG was stored by dissolving in water at 250 mM. The conversion of 
increasing concentrations of PNPG to PNP, in the presence of 10 nM enzyme, was measured in the 
presence of increasing concentrations of putative inhibitors; zero-substrate and zero-inhibitor controls 
were carried out at the same time. Reactions were conducted in 96-well, clear-bottom assay plates 
(Costar, Tewksbury, MA) at 37 
o
C in 50 µL of total volume. The reaction consisted of 10 µL of assay 
buffer (5% DMSO and 500 mM HEPES, pH 7.4), 5 µL of inhibitor solution (various concentrations), 5 
µL of 100 nM enzyme, and 30 µL of substrate (various concentrations).  Product formation was 
calculated by measuring the change in absorbance over time at 410 nm using a PHERAstar Plus 
microplate reader (BMG Labtech, Ortenberg, Germany). The acquired data were analyzed using 
Microsoft Excel and Sigmaplot 11.0. From these data, Ki values were calculated for each of the inhibitors.  
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A related assay was employed to calculate the IC50 values in the following manner. An analogous 
50 µL reaction, consisting of enzyme (1 nM final), buffer, PNPG (1 mM final), and variable 
concentrations of the inhibitors, was incubated at 37 
o
C for 6 hours to allow the reaction to reach 
equilibrium and then quenched with 100 µL 0.2 M sodium carbonate. The percent inhibition for each 
concentration of inhibitor was calculated based on changes in absorbance and used to plot a dose-
response curve. The IC50 value was calculated as the concentration of inhibitor that produced 50% in vitro 
inhibition.  The same assay was performed with purified bovine liver β-glucuronidase with PNPG as the 
substrate. 
We also tested the ability of these compounds to inhibit β-glucuronidase activity in E. coli cells. 
We grew HB101 E. coli cells, transformed with the pET-28a vector containing the β-glucuronidase gene, 
to an OD600 of 0.6 in LB medium and used a small aliquot in an assay similar to the in vitro IC50 assay 
described above. The cells (39 µL) were incubated with 1 µL of variable concentrations of inhibitor and 
10 µL of 1 mM PNPG at 37 
o
C for 6 hours. The reaction was quenched with 100 µL 0.2 M sodium 
carbonate. The amount of substrate turnover and therefore the amount of inhibition is calculated from the 
change in absorbance compared to zero-inhibitor controls. EC50 values were calculated as the amount of 
inhibitor necessary to produce 50% inhibition.  The in vitro and cell-based assays employed here were 
similar to those reported previously (74). 
Toxicity of Inhibitors toward Cultured Cells  
The toxicity of inhibitors to bacterial cells was examined by incubating HB101 E. coli cells, 
transformed with the pET-28a vector containing the β-glucuronidase gene,  grown to an OD600 of 0.6 in 
LB medium with each compound, as well as DMSO and ampicillin as controls, for 6 hours. Cell 
survivability was measured by plating a 10
-5
 dilution of the cells on LB media enriched with kanamycin. 
After overnight incubation, colonies were counted to quantify cell viability.  We used a similar assay to 
assess the inhibitor’s toxicity toward cultured HCT116 human colon cancer cells, which were grown and 
cultured in DMEM media. Aliquots of HCT116 cells were incubated with 100 µM of each lead for 24 
hours. The resulting viability of the cells was quantified by using the CellQuanti-Blue™ Cell Viability 
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Assay Kit (BioAssay Systems, Hayward, CA). Cells are incubated with CellQuanti-Blue™ Reagent and 
fluorescence was measured. 
Crystal Structure Determination  
Crystals of EcβG were obtained at 2 mg/mL protein with 30-fold molar excess Inhibitor R1 in 
16% PEG-3350 (w/v), 200 mM magnesium acetate, and 0.02% sodium azide (w/v) at 16 °C. Crystals first 
appeared after 5 days, and were immediately cryo-protected with perfluoropolyether vacuum pump oil 
(Sigma-Aldrich, St. Louis, MO) and flash-cooled in liquid nitrogen. Diffraction data were collected on the 
23-ID beam line at GM/CA-CAT (Advanced Photon Source, Argonne National Laboratory). Data in 
space group C2 were indexed and scaled using HKL2000 (93) to 2.39 Å resolution. The asymmetric unit 
contained two monomers. The structure was determined with Phaser (94) using molecular replacement 
with the apo EcβG structure (PDB ID 3K46) as a search model. The structure was refined using simulated 
annealing and torsion angle refinement with the maximum likelihood function target in CNS, and 
monitored using both the crystallographic R and cross-validating R-free statistics (95). The software suite 
PHENIX (96) was also employed for B-factor and TLS refinement. The model was manually adjusted 
using Coot (97) and 2Fo-Fc and Fo-Fc electron density maps. The ligand model and definition files were 
generated using PRODRG (98) and were placed into electron density in the active site of both monomers 
in the asymmetric unit. 
Toxicity Studies in Mice 
Animal experiments were performed according to the Institutional Animal Care and Use 
guidelines approved by the Institutional Animal Care and Use Committee of the Albert Einstein College 
of Medicine, Bronx, New York. CPT-11 (20 mg/mL) and Inhibitor R1 (100 μg/mL) were dissolved in 
0.25% (w/v) carboxymethylcellulose sodium salt to make stock solutions.  As a vehicle control, all 
animals received an equivalent volume (compared to experimental groups) of 0.25% (w/v) 
carboxymethylcellulose sodium salt solution. BALB/cJ female mice were divided into four groups: Group 
1, vehicle controls received equivalent volume of 0.25% (w/v) carboxymethylcellulose sodium salt 
solution intraperitoneally (i.p.) and by oral gavage (~100 µL twice per day); Group 2, Inhibitor R1 
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gavaged (10 µg/day) twice per day (every 10 hours) starting on day 
–
1 with oral gavage of 0.25% (w/v) 
carboxymethylcellulose sodium salt solution, and i.p. once per day; Group 3, CPT-11 injected (50 mg/kg) 
i.p. once daily in the morning with oral gavage of 0.25% (w/v) carboxymethylcellulose sodium salt 
solution; Group 4, CPT-11 injected (50mg/kg) i.p. once daily in the morning, and Inhibitor R1 gavaged 
(10 µg/day) twice per day (every 10 hours). Total injected volume was identical for each animal. Mice 
were examined daily for signs of diarrhea (fecal staining of skin, lose watery stool) and bloody diarrhea 
(black sticky stool) using methods previously published (74, 99).  Previous studies indicate that dosing at 
~60-80 mg/kg/day of CPT-11 for 4 days allows for observation of delayed diarrhea around 15 days (100). 
A dosing scheme of 50 mg/kg/day, once daily for 9 days, was chosen with the intention of accelerating 
the onset of diarrhea while preventing death. As outlined previously, 50 mg/kg CPT-11 in mice is roughly 
equivalent to the 5 mg/kg typical human CPT- 11 dose based on differences in body surface area (63, 
100).  
Bioavailability Studies in Mice 
 Healthy male Swiss Albino mice (10-12 weeks old) purchased from In Vivo Biosciences were 
divided into 4 groups of 4 mice each. The first group received a control IV dose of Inhibitor 1. The 
second group was pretreated with an oral dose of a formulation of 1-aminobenzotriazole (ABT) at 50 
mg/kg 2 hours prior before receiving an IV dose of Inhibitor 1. The third group received an oral dose of 
Inhibitor 1 in a suspension formulation at 3 mg/kg. The fourth group received the same oral dose of 
Inhibitor 1 but was first treated with the same formulation of ABT as group two. The first and third 
groups received a control oral dose of vehicle in place of ABT treatment. Blood samples (approximately 
60 µL) were collected at set time intervals (0.08, 0.25, 0.5, 1, 2, 4, 8, and 24 hr) after treatment with 
Inhibitor 1. Plasma was immediately harvested via centrifugation after collection of blood samples and 
store at -70 
o
C before analysis. Protein were precipitated from samples using acetonitrile and analyzed by 
LC-MS/MS.  
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PK Studies in Mice 
 Healthy mice received the same dosing schedule as the toxicity studies outlined previously. In 
short, groups of mice received either vehicle (0.25% (w/v) carboxymethylcellulose sodium salt solution), 
CPT-11 (injected 50 mg/kg i.p. once daily in the morning with oral gavage of 0.25% (w/v) 
carboxymethylcellulose sodium salt solution), or CPT-11 plus Inhibitor 1 (CPT-11 injected 50mg/kg i.p. 
once daily in the morning, and Inhibitor 1 gavaged orally 10 µg/day twice per day every 10 hours). 
Plasma samples were taken at regular time intervals. Samples were analyzed by mass spectrometry 
(Thermo LTQ Orbitrap Discovery) following calibration using commercially-available purified CPT-11, 
SN-38, and SN-38G. These experiments were performed by the lab of William C. Zamboni, PharmD, 
PhD (UNC Chapel Hill). 
Tumor Studies in Mice 
 Efficacy experiments in mice were performed according to the Institutional Animal Care and Use 
guidelines approved by the Institutional Animal Care and Use Committee of the Albert Einstein College 
of Medicine, Bronx, New York. Healthy BALB/cJ female mice were divided into three groups of three 
mice each. Group 1 was untreated controls. Group 2 received CPT-11 treatment. Group 3 received CPT-
11 treatment with pre-treatment with Inhibitor 1. Mice were initially xenografted with tumors of similar 
volume. Following treatment, tumors were excised. Efficacy of CPT-11 was quantified by measuring the 
final volume of the tumors.  
  
3.4 Results 
3.4.1 Rational Design of Novel Inhibitor Analogues 
We have previously characterized a group of inhibitors discovered via high-throughput screening 
against a range of β-glucuronidase enzymes from E. coli, Streptococcus agalactiae, and Clostridium 
perfringens (EcβG, SaβG, and CpβG, respectively; Chapter 2). Our next goal was to make chemical 
modifications to the most promising compounds in order to strengthen in vivo efficacy. Contrary to a 
typical drug development process, our system necessitates that compounds have a low bioavailability via 
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GI absorption. As opposed to a typical drug that requires robust absorption into the systemic circulation, 
these compounds are designed to stay in the digestive tract and thus, have a low bioavailability. Focusing 
on the modifications of the O-ethyl group on Inhibitor 1, we designed analogues in order to decrease their 
ability to be absorbed through cell membranes (Figure 3.1). Compounds were designed with the 
assistance of Dr. Jian Jin (Center for Integrative Chemical Biology and Drug Discovery, UNC-Chapel 
Hill), and were synthesized by CDS. By increasing the charge of that side chain, we believed that we 
could decrease the gastrointestinal (GI) absorption of these compounds. Of the synthesized compounds, 
two (Inhibitor R1 and Inhibitor R3) were shown to maintain their ability to inhibit EcβG. 
 
 
 
3.4.2 Inhibitory Characterization of Novel Analogues 
 We first characterized the novel analogues against EcβG in vitro as well as against cultured E. 
coli cells using the substrate p-nitrophenyl glucuronide (PNPG) (Table 3.1).  Although the newly 
synthesized compounds maintained their ability to inhibit in vitro and in cell-based assays, there was a 
loss in potency. Compared to Inhibitor 1 (Ki = 160 nM), Inhibitor R1 (Ki = 1900 nM) had a10-fold 
decrease in potency, and Inhibitor R3 (Ki = 610 nM) exhibited a 4-fold decrease. In cell-based assays, 
Inhibitors R1 and R3 produced an approximately 3- and 2-fold decrease in their ability to inhibit β-
glucuronidase activity (EC50 = 4.5 µM, EC50 = 3.1 µM, respectively). The drop in potency, however, 
Figure 3.1. Chemical structures of novel analogues and the parent compound from which they were 
synthesized. 
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would not necessarily preclude the compounds from being used in in vivo experiments, but we 
hypothesized that it would result in reduced efficacy of amelioration of drug-induced toxicity.  
 
 
3.4.3 Crystal Structure of EcβG in Complex with Inhibitor R1 
 In order to better understand differences in their inhibitory potency, we determined the crystal 
structure of EcβG in complex with Inhibitor R1 (Table 3.2, Figure 3.2A). The protein crystallized as a 
dimer in the asymmetric unit with one Inhibitor R1 molecule located at the active site in each monomer. 
The unit cell is analogous to each of the previously determined inhibitor-bound structures of EcβG. By 
focusing on the ligand binding pocket, adjacent to the active site, we were surprised to find a different 
orientation of the inhibitor and the active site residues relative to previously determined structures of 
Inhibitor R1 homologues, Inhibitor 2 and Inhibitor 3 (74). In previous structures, two tyrosines (Tyr-469 
and Tyr-472) located adjacent to the active site would “flip in” upon inhibitor binding relative to the un-
liganded structure. However, presented here is the first case where upon binding of an inhibitor, the 
tyrosines remain in their un-liganded conformation as evidenced by the apo EcβG crystal structure 
(Figure 3.2B). It is not clear whether this enzyme orientation explains the reduced potency of Inhibitor 
R1 relative to Inhibitor 1. More data with compounds found to bind in the same manner as Inhibitor R1 
and to have similarly reduced potency would be required to confirm this hypothesis. 
Table 3.1. Inhibition against  EcβG 
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3.4.4 Inhibitory Characterization of Novel Analogues against SaβG and CpβG 
We next tested the inhibitor analogues against purified SaβG and CpβG. Although Inhibitor 1 
maintained potency, the analogues displayed no apparent inhibition (Table 3.3). In order to better 
understand this difference, we compared the Inhibitor R1-bound EcβG structure to previously determined 
Table 3.2. Crystallographic statistics of EcβG in complex with Inhibitor 
R1 
 
 
 
Figure 3.2. (A) Crystal structure of EcβG dimer (green) in complex with Inhibitor R1 (gray), bound 
at the active site of each monomer. (B) Overlay of ligand binding tyrosines of Inhibitor R1-bound 
structure with previously determined structures: EcβG (purple) bound to Inhibitor 2 (yellow) (PDB 
ID 3LPG), EcβG (blue) bound to Inhibitor 8 (orange) (PDB ID 4JHZ), and un-liganded EcβG (pink) 
(PDB ID 3K46). 
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un-liganded structures of SaβG and CpβG. Despite the high degree of structural similarity between 
species, focusing on the ligand-binding tyrosines, they are in the same “flipped-in” conformation for the 
un-liganded SaβG and CpβG structures as in the ligand-bound forms of EcβG and in the opposite position 
as the un-liganded and the Inhibitor R1-bound EcβG structure (Figure 3.3A). The sequences directly 
adjacent to the tyorsines are highly conserved among EcβG, SaβG and CpβG (Figure 3.3B), so there is 
no clear explanation for these observed differences. Additional mutagenesis or crystallographic analysis is 
needed. 
 
 
 
 
 
 
 
 
Table 3.3. Inhibition against SaβG and CpβG. 
 
 
Figure 3.3. (A) Overlay of ligand binding tyrosines of EcβG (green) in complex with Inhibitor R1 
(gray) with previously determined structures: CpβG (yellow) (PDB ID 4JKL), SaβG (blue) in space 
group I222 (PDB ID 4JKK), and SaβG (pink) in space group P21212 (PDB ID 4JKM). (B) Sequence 
alignment of flexible, active site tyrosines and adjacent residues for EcβG, SaβG, and CpβG. Based 
on residue numbering of Inhibitor R1-bound EcβG, the alignment begins at Asp-458 and ends at 
Gly-476. Symbols represent the relative amount of sequence conservation 
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3.4.5 Inhibitor Plasma Pharmacokinetic Profile 
 We next investigated the plasma pharmacokinetics of each inhibitor to test our original conceit - 
that these analogues would display decreased systemic absorption than their parent compound. Mice were 
given a 3 mg/kg dose of Inhibitor 1, R1, or R3, either orally or intravenously (IV) (Figure 3.4). There 
were 9 mice in each group, and each time point consists of samples from 3 mice such that the same 
groups of 3 mice were sampled for each 4
th
 time point. In each case, both routes produced a peak half-life 
of less than 1 hour. Unsurprisingly, the IV route produced larger peaks. After IV administration, Inhibitor 
1 reached its peak half-life at 0.25 hours, longer than Inhibitors R1 and R3, which reached their peak half-
life at 0.08 hours (Figure 3.4A). Inhibitor R1 had a lower peak concentration (1400 ng/mL) than either 
Inhibitor 1 (4800 ng/mL) or Inhibitor R3 (5500 ng/mL). The same trends between inhibitors were 
observed following oral administration (Figure 3.4B). These data present Inhibitor R1 as an improved 
clinical candidate for the purpose of alleviating drug-induced toxicity mediated by bacterial β-
glucuronidases.  
 
 
 
 
3.4.6 Oral Bioavailability of Novel Analogues 
 We further tested our hypothesis by measuring the oral bioavailability (%F) of the inhibitors, the 
amount of the compound that reaches systemic circulation (Table 3.4). Healthy Swiss Albino mice 
Figure 3.4. Mice (N = 9) were given either an intravenous (A) or oral (B) dose of the inhibitors. 
Concentrations of the compound were then measured in the blood at regular time intervals (N = 3). 
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received a 3 mg/kg dose of each inhibitor and plasma samples were drawn at regular time intervals. In 
support of our strategy, the bioavailability of the inhibitor analogues were decreased 6- and 3- fold from 
21% for Inhibitor 1 to 3.5% and 6.3% for Inhibitors R1 and R3, respectively. These results, however, do 
not take into account first-pass metabolism of each of the dosed inhibitors, so we interrogated how 
degradation of these xenobiotic compounds in the liver contributed to decreased bioavailability. To do 
this, mice were pretreated with 1-aminobenzotriazole (ABT) at 50 mg/kg two hours prior to the same 
dose of inhibitor. ABT is a pan-inhibitor of cytochrome P450 enzymes, a main route of initial xenobiotic 
degradation. By eliminating cytochrome P450 activity, we see how first-pass metabolism affects 
compound levels in plasma. In that case, the bioavailability of Inhibitor 1 increased from 21% to 99%, 
indicating that the majority of Inhibitor 1 given to mice is subject to cytochrome P450 metabolism. The 
bioavailability of Inhibitor R3 similarly increased from 6.3% to 74%. Inhibitor R1, however, only 
produced a relatively minimal increase, from 3.5% to 12%, indicating that more of Inhibitor R1 is not 
subject to the same degree of metabolism by cytochrome P450 enzymes in mice as Inhibitors 1 or R3. 
  
 
 
3.4.7 Comparison of the Alleviation of CPT-11 Diarrhea by Novel Analogues 
 Although our attempts were met with only partial success, we took this opportunity to understand 
how each of these elements factor into greater in vivo success. To test this, we performed an experiment 
where a group of mice were treated with CPT-11.Another group of mice would be given the same dose of 
CPT-11 and pretreated with either Inhibitor 1 or R1. In doing this, we saw that Inhibitor 1was more 
effective at alleviating the drug-induced diarrhea than Inhibitor R1 (Figure 3.5). For example, on day 8 
Table 3.4. Oral bioavailability (%F) of inhibitors in mice with and without the pan-cytochrome p450 
inhibitor, ABT. 
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following CPT-11 treatment, 14% of mice had developed bloody diarrhea in the group pre-treated with 
Inhibitor R1, while in the same time frame, no mice had developed the same symptoms in the group pre-
treated with Inhibitor 1.  
 
 
 
3.4.8 Effects of Pre-treatment with Inhibitor 1 on CPT-11 Plasma Pharmacokinetic Profile 
Although we have shown that inhibition of bacterial β-glucuronidase is able to alleviate the dose-
limiting diarrhea in mice, we have not shown that if, by doing so, we are impacting the efficacy of CPT-
11 by altering its pharmacokinetics. The efficacy of some chemotherapeutics has been postulated to 
require enterohepatic recirculation of reactivated metabolites created by the GI β-glucuronidases (e.g., 
sorafenib), so it is important to understand if inhibition impacts plasma levels of CPT-11 and its 
metabolites SN-38 and SN-38G. Thus, we measured the plasma pharmacokinetic profile of CPT-11 in 
mice with and without pretreatment of Inhibitor 1. CPT-11 and Inhibitor 1 dosing were performed as 
described in previous toxicity studies (74).  As shown in Figure 3.6, we observed no change in the 
pharmacokinetic profile of CPT-11. These data indicate that levels of CPT-11 and its metabolites in the 
plasma of mice are not impacted by inhibition of GI-associated bacterial β-glucuronidases in these 
animals. 
Figure 3.5. Alleviation of CPT-11-induced diarrhea in mice that were give a dose of CPT-11 either 
with or without pretreatment of either Inhibitor 1 or Inhibitor R1. 
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3.4.9 Effects of Pre-treatment with Inhibitor 1 on Anti-tumor Ability of CPT-11 
By demonstrating that SN-38 plasma levels remain the same in the presence of the bacterial β-
glucuronidase inhibitor, Inhibitor 1, it suggests that antitumor efficacy of CPT-11 would also remain 
intact.  Thus, we tested how Inhibitor 1 would affect the anti-tumor activity of CPT-11 in preliminary 
studies with only a small number of mice, using doses of CPT-11 and Inhibitor 1 employed previously. 
Mice were transplanted with xenografted tumors grown from primary cells taken during surgery from a 
colon cancer patient at Einstein College of Medicine. Groups of these mice were then untreated (N = 4), 
treated with CPT-11 (N = 3), or pretreated with Inhibitor 1 prior to CPT-11 treatment (N = 3). We saw no 
change in the anti-tumor activity of CPT-11, as measured by reduction in tumor size, with or without 
pretreatment with Inhibitor 1 (Figure 3.7).  These results provide the first data to support the conclusion 
that the GI toxicity of CPT-11 can be reduced without impacting anticancer activity and indicate that with 
more work on dosing regimen, improved antitumor efficacy could also be achieved. 
Figure 3.6. Effects on plasma pharmacokinetic profile of CPT-11 after pretreatment with Inhibitor 1 
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3.5 Discussion 
 Previous work from this lab has led to the discovery of non-toxic small-molecule β-glucuronidase 
inhibitors selective for the bacterial enzyme over the mammalian orthologue or familial bacterial 
enzymes. These inhibitors were tested in order to develop a potential therapeutic for use in humans in 
order to alleviate GI toxicity as a side effect of the reactivation of conjugated drug metabolites by 
symbiotic GI-associated microbiota. The development of a lead candidate, however, requires more than 
potent in vitro inhibition. It must also demonstrate essential in vivo properties for use as a drug. For most 
drugs that require trafficking to sites throughout the body, one crucial property is bioavailability, the 
amount of the drug that reaches systemic circulation. For our purposes, however, the site of action for 
potential therapeutics is not reached via systemic circulation. Instead, we seek to develop a compound 
with a low bioavailability, such that the compound may possibly stay in the digestive tract where it 
impacts the β-glucuronidase activity of the microbiota population that naturally resides in the host 
intestine. Therefore, in this investigation, we sought to chemically modify a lead compound in order to 
decrease its bioavailability.  
 The O-ethyl side chain of the lead compound, termed Inhibitor 1, was modified to increase the 
overall charge in the hopes of decreasing GI absorption (Figure 3.1). Two analogues that were produced, 
termed Inhibitors R1 and R3, maintained potent inhibition of EcβG (Table 3.1). We then measured the 
Figure 3.7. Effects on anti-tumor efficacy of CPT-11 after pretreatment with Inhibitor 1 
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bioavailability for each compound in mice. Indeed, both analogues produced a marked decrease in the 
amount of compound to reach systemic circulation compared to the parent compound (Table 3.4). These 
results were magnified when, upon repeating the experiment but pretreating the mice with a pan-
cytochrome P450 inhibitor (ABT), eliminating the variable of degradation in the liver that may lower the 
measured bioavailability, only Inhibitor R1 maintained a sufficiently low bioavailability. These data 
indicate that the modifications made to Inhibitor R1 altering its overall charge will lower bioavailability. 
Before we accept that Inhibitor R1 experiences more residence time in the intestine where it 
could effectively inhibit bacterial β-glucuronidases, we must make the following assumptions.  First, 
because we have not directly measured the levels of the inhibitors in the feces of treated mice, we cannot 
conclude that reductions in bioavailability correlate with increases in the GI lumen presence of these 
compounds.  Second, we are assuming that the unmodified compounds are the only forms of these 
chemicals that are active on target GI bacterial enzymes.  It is possible that metabolic drug products or 
microbial processing of these compounds will reduce drug-induced toxicity. A complete pharmacokinetic 
profile of each compound would be required to understand the roles played by each metabolite in diarrhea 
amelioration. 
Unfortunately, the analogues proved ineffective at inhibiting purified β-glucuronidases from two 
GI-associated bacterial species, Clostridium perfringens and Streptococcus agalactiae (Table 3.3). It is 
possible that only enzymes more closely related to EcβG (e.g., from the same phylum) would still 
maintain inhibition by Inhibitor R1, while more distantly related enzymes (e.g., Firmicutes such as SaβG 
and CpβG) would not. Sequence alignment between these enzymes does not clarify the differences 
(Figure 3.3B), but crystallographic analysis highlights ligand-binding tyrosines that are “flipped-in” in 
un-liganded SaβG and CpβG structures relative to the Inhibitor R1-bound structure of EcβG (Figure 
3.3A). Interestingly, the tyrosines had previously only been observed to “flip-in” to accommodate binding 
based on structures of inhibitor-bound EcβG relative to the un-liganded EcβG structure. While the SaβG 
and CpβG structures present the enzymes in their un-liganded forms, these comparisons allow us to draw 
preliminary conclusions. For instance, contrary to EcβG structures that show that these tyrosines are 
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dynamic upon ligand binding, it is possible that these tyrosines are rigid in the “flipped-in” position in 
SaβG and CpβG. For all of the previously studied inhibitors, this is not a problem because the tyorsines 
need to be “flipped-in” to allow for proper binding contacts. Inhibitor R1 is the first case of a ligand that 
necessitates the opposite position for these tyrosines, as seen in the wild-type EcβG structure. Thus, if 
these tyrosines in SaβG and CpβG are not dynamic, but rigid instead, then Inhibitor R1 will not be an 
effective broad-spectrum inhibitor, as observed experimentally. This leads one to believe that Inhibitor 1, 
which is more effective in vivo, binds in a mode similar to other structurally similar compounds, Inhibitor 
2 and Inhibitor 3 where the tyrosines are “flipped-in” (74). Further crystallographic analysis and testing 
with additional bacterial enzymes would be necessary to support or refute this hypothesis. 
Since the three tested enzymes only represent a portion of the total β-glucuronidase activity in GI-
associated microbiota, the lack of observed broad-spectrum inhibition does not necessarily preclude the 
analogues from in vivo success. Thus, we tested Inhibitor R1 in vivo to better understand whether broad-
spectrum inhibitory efficacy or low bioavailability translates to the ability of the compound to alleviate 
CPT-11-induced diarrhea (Figure 3.5). From these results in mice indicating that Inhibitor 1 is more 
effective at alleviating the dose-limiting toxic side effect of CPT-11, it appears the ability for a compound 
to potently inhibit a range of β-glucuronidase enzymes across bacterial species makes a compound a more 
effective therapeutic.  A full pharmacokinetic profile of the inhibitors would be necessary to understand 
this possibility, with the goal of finding an effective broad-spectrum inhibitor that possesses low 
bioavailability. The success of Inhibitor R1 producing a lower bioavailability should direct us to develop 
more analogues that possess both of these characteristics.  
Still, we moved forward with Inhibitor 1 as a lead candidate. Although it has proven effective at 
alleviating drug-induced toxicity, there are questions that remain to be answered regarding its effect on 
the anti-tumor ability of CPT-11. We first tested Inhibitor 1 in a model to measure effects on the plasma 
pharmacokinetic profile of CPT-11 (Figure 3.6). Comparing groups of mice that received CPT-11 alone 
and mice that received CPT-11 but were pretreated with Inhibitor 1, there were no significant differences 
in the pharmacokinetics of CPT-11 in plasma, including SN-38 or SN-38G, suggesting that Inhibitor 1 
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should not affect the anti-tumor efficacy of CPT-11, and more broadly, that the efficacy of CPT-11 does 
not rely on the enterohepatic circulation of its active metabolite, SN-38. This is an important result 
because it has been hypothesized that, in addition to mediate toxicity, bacterial reactivation of SN-38 in 
the intestinal lumen is critical for the broad anti-cancer ability of CPT-11 via enterohepatic circulation. 
Therefore, if we can show that levels of SN-38, the active metabolite, in systemic circulation are not 
effected by β-glucuronidase inhibition, then it follows that the anti-cancer efficacy  of CPT-11 should not 
be effect either. 
More directly, we tested the system of inhibition in a model that could alter the efficacy of CPT-
11 in reducing tumor size (Figure 3.7). Groups of mice were implanted with foreign tumors and then 
received no treatment, CPT-11 only, or CPT-11 preceded by an oral dose of Inhibitor 1. Strikingly, upon 
pretreatment with Inhibitor 1, there were no changes in the ability of CPT-11 to shrink the tumor. These 
results are preliminary and thus, do not show a statistical significance, but qualitatively, the results are 
encouraging and warrant further experimentation.  
Here, we have shown that we are able to chemically modify a putative β-glucuronidase inhibitor 
to profoundly change its in vivo properties. Unfortunately, these alterations, in this case, also produced 
negative results in vitro. Testing these conflicting results, the ability to alleviate drug-induced toxicity 
indicated that the capacity of the inhibitors to impact a range of enzymes from different bacterial species 
outweighs improved in vivo bioavailability. Taking the lead compound, Inhibitor 1, we further 
investigated its biological relationship to CPT-11. We demonstrated that, in mice, pretreatment with 
Inhibitor 1 does not impact that plasma pharmacokinetic profile of CPT-11. Strikingly, preliminary results 
indicate that Inhibitor 1 does not affect the ability of CPT-11 to shrink tumors in mice. These data will 
allow us to move forward with a focused plan to chemically modify lead compounds in order to produce a 
more robust in vivo result. 
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Chapter 4 
Design of Novel Inhibitors with Increased Potency Using Structural and Chemical Biology  
 
4.1 Summary 
 Drug-induced toxicity represents a serious, yet often underreported and difficult to treat, 
complication in chronic and acute therapeutics. For example, CPT-11, used for treatment of colorectal 
cancer, and NSAIDs, the most widely prescribed class of drugs in the world, are hindered by 
gastrointestinal complications, which may be fatal. The symbiotic GI microbiota, specifically a hydrolytic 
enzyme known as β-glucuronidase, have been implicated in mediating these toxicities through the 
reactivation of drug metabolites. Targeted bacterial β-glucuronidase inhibitors have been shown to 
alleviate these toxicities in mouse models. We synthesized analogues of the most potent compound with 
the goal of increasing potency by focusing on the solvent exposed side chain of the ligand based on 
crystallographic analysis. Kinetic analysis demonstrated a slight increase in potency in assays with three 
bacterial β-glucuronidases. One compound, however, exhibited a 10-fold increase in potency in IC50 
assays against the enzyme from Clostridium perfringens perhaps due to a unique symmetry in the side 
chains, observed in crystal structures producing multiple conformations of bound inhibitor. This 
compound is the most potent β-glucuronidase inhibitor known to date.  
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4.2 Materials and Methods 
Reagents 
 The assay substrate p-nitrophenyl β-D-glucuronide (PNPG) was purchased from Sigma-Aldrich 
(St. Louis, MO). Inhibitor 9 was synthesized by Asinex, Inc. (Winston-Salem, NC). Inhibitors were 
identified by high-throughput screening and secondary validation was performed in-house (37). β-
glucuronidase (EC 3.2.1.31) from E. coli, S. agalactiae, and C. perfringens (EcβG, SaβG, and CpβG, 
respectively) were expressed and purified as described previously (74). Purified β-glucuronidase was 
stored in 20 mM HEPES, 50 mM NaCl, pH 7.4 at ≈10 mg/mL at –80 oC.  
Kinetic and Equilibrium Inhibition Assays.  
Inhibition assays were conducted by measuring the β-glucuronidase-catalyzed conversion of 
PNPG to p-nitrophenol (PNP). The conversion of increasing concentrations of PNPG to PNP, in the 
presence of 10 nM enzyme, was measured in the presence of increasing concentrations of putative 
inhibitors; zero-substrate and zero-inhibitor controls were carried out at the same time. Reactions were 
conducted in 96-well, clear-bottom assay plates (Costar, Tewksbury, MA) at 37 
o
C in 50 µL of total 
volume. The reaction consisted of 10 µL of assay buffer (5% DMSO and 500 mM HEPES, pH 7.4), 5 µL 
of inhibitor solution (various concentrations), 5 µL of 100 nM enzyme, and 30 µL of substrate (various 
concentrations).  Product formation was calculated by measuring the change in absorbance over time at 
410 nm using a PHERAstar Plus microplate reader (BMG Labtech, Ortenberg, Germany). The acquired 
data were analyzed using Microsoft Excel and Sigmaplot 11.0. From these data, Ki values were calculated 
for each of the inhibitors.  
A related assay was employed to calculate the IC50 values in the following manner. An analogous 
50 µL reaction, consisting of enzyme (1 nM final), buffer, PNPG (1 mM final), and variable 
concentrations of the inhibitors, was incubated at 37 
o
C for 6 hours to allow the reaction to reach 
equilibrium and then quenched with 100 µL 0.2 M sodium carbonate. The percent inhibition for each 
concentration of inhibitor was calculated based on changes in absorbance and used to plot a dose-
response curve. The IC50 value was calculated as the concentration of inhibitor that produced 50% in vitro 
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inhibition.  The same assay was performed with purified bovine liver β-glucuronidase with PNPG as the 
substrate. 
We also tested the ability of these compounds to inhibit β-glucuronidase activity in E. coli cells. 
We grew HB101 E. coli cells, transformed with the pET-28a vector containing the β-glucuronidase gene, 
to an OD600 of 0.6 in LB medium and used a small aliquot in an assay similar to the in vitro IC50 assay 
described above. The cells (39 µL) were incubated with 1 µL of variable concentrations of inhibitor and 
10 µL of 1 mM PNPG at 37 
o
C for 6 hours. The reaction was quenched with 100 µL 0.2 M sodium 
carbonate. The amount of substrate turnover and therefore the amount of inhibition is calculated from the 
change in absorbance compared to zero-inhibitor controls. EC50 values were calculated as the amount of 
inhibitor necessary to produce 50% inhibition.  The in vitro and cell-based assays employed here were 
similar to those reported previously (74). 
Crystal Structure Determination  
Crystals of EcβG were obtained at 2 mg/mL protein with 30-fold molar excess Inhibitor 9-77 in 
18% PEG-3350 (w/v), 250 mM magnesium acetate, and 0.02% sodium azide (w/v) at 16°C and with 30-
fold molar excess Inhibitor 9-79 in 21% PEG-3350 (w/v), 300 mM magnesium acetate, and 0.02% 
sodium azide (w/v) at 16 °C and a 2:1 ratio of protein to crystallant. Crystals first appeared after 5 days, 
and were immediately cryo-protected with perfluoropolyether vacuum pump oil (Sigma-Aldrich, St. 
Louis, MO) and flash-cooled in liquid nitrogen. Diffraction data were collected on the 23-ID beam line at 
GM/CA-CAT (Advanced Photon Source, Argonne National Laboratory). Data in space group C2 were 
indexed and scaled using HKL2000 (93) to 2.79 Å resolution and 2.28 Å resolution for Inhibitors 9-77 
and 9-79, respectively. The asymmetric units contained two monomers. The structures were determined 
with Phaser (94) using molecular replacement with the recent apo EcβG structure (PDB ID 3K46) as a 
search model. The structures were refined using simulated annealing and torsion angle refinement with 
the maximum likelihood function target in CNS, and monitored using both the crystallographic R and 
cross-validating R-free statistics (95). The software suite PHENIX (96) was also employed for B-factor 
and TLS refinement. The models were manually adjusted using Coot (97) and 2Fo-Fc and Fo-Fc electron 
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density maps. The ligand models and definition files were generated using PRODRG (98) and were 
placed into electron density in the active site of each monomer in the asymmetric unit. 
Toxicity Studies in Mice 
Animal experiments were performed according to the Institutional Animal Care and Use 
guidelines approved by the Institutional Animal Care and Use Committee of the Albert Einstein College 
of Medicine, Bronx, New York. CPT-11 (20 mg/mL) and Inhibitor 9 (100 μg/mL) were dissolved in 
0.25% (w/v) carboxymethylcellulose sodium salt to make stock solutions.  As a vehicle control, all 
animals received an equivalent volume (compared to experimental groups) of 0.25% (w/v) 
carboxymethylcellulose sodium salt solution. BALB/cJ female mice were divided into four groups: Group 
1, vehicle controls received equivalent volume of 0.25% (w/v) carboxymethylcellulose sodium salt 
solution intraperitoneally (i.p.) and by oral gavage (~100 µL twice per day); Group 2, Inhibitor 9 gavaged 
(10 µg/day) twice per day (every 10 hours) starting on day 
–
1 with oral gavage of 0.25% (w/v) 
carboxymethylcellulose sodium salt solution, and i.p. once per day; Group 3, CPT-11 injected (50 mg/kg) 
i.p. once daily in the morning with oral gavage of 0.25% (w/v) carboxymethylcellulose sodium salt 
solution; Group 4, CPT-11 injected (50mg/kg) i.p. once daily in the morning, and Inhibitor 9 gavaged (10 
µg/day) twice per day (every 10 hours). Total injected volume was identical for each animal. Mice were 
examined daily for signs of diarrhea (fecal staining of skin, lose watery stool) and bloody diarrhea (black 
sticky stool) using methods previously published (74, 99).  Previous studies indicate that dosing at ~60-80 
mg/kg/day of CPT-11 for 4 days allows for observation of delayed diarrhea around 15 days (100). A 
dosing scheme of 50 mg/kg/day, once daily for 9 days, was chosen with the intention of accelerating the 
onset of diarrhea while preventing death. As outlined previously, 50 mg/kg CPT-11 in mice is roughly 
equivalent to the 5 mg/kg typical human CPT- 11 dose based on differences in body surface area (63, 
100).  
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4.3 Results 
4.3.1 Design of Novel Inhibitor Analogues 
 The crystal structure of Inhibitor 9 in complex with a bacterial β-glucuronidase highlighted 
structural features of Inhibitor 9 critical for binding. This structure was determined and refined by Dr. 
Bret Wallace, a previous graduate student in the Redinbo Lab. Of particular interest is the terminal 
piperazine group that bound in the active site gorge, closest to the catalytic residues (Figure 4.1A). To 
test the theory that the hydrogen-bond potential of the nitrogen is critical for inhibition, we synthesized an 
analogue of Inhibitor 9 with the piperazine nitrogen replaced by a carbon to create a piperidine group 
(Inhibitor 9-70; Figure 4.1B). As expected, Inhibitor 9-70 displayed no inhibition against purified 
bacterial β-glucuronidases from E. coli, Streptococcus agalactiae, and Clostridium perfringens (EcβG, 
SaβG, and CpβG, respectively) (data not shown). This is an important confirmation of the structure-
activity relationship considered critical to Inhibitor 9 efficacy against these bacterial enzymes and 
validates the conclusion that the piperazine makes crucial contacts with the active site.   
  
 
 
 
  
4.3.2 Characterization of Novel Inhibitor Analogues 
Based on the Inhibitor 9-bound CpβG structure (Figure 4.1A), we targeted the solvent-exposed 
morpholine group for modification to minimize risk of reducing potency and, thus, synthesized a small 
Figure 4.1. A) Previously determined x-ray crystal structure of Inhibitor 9 (purple) in complex with 
CpβG (yellow) highlighting the ligand-binding pocket. The terminal piperazine group binds adjacent 
to active site tyrosines and catalytic glutamic acid residues. The solvent-exposed morpholine group 
does not make protein contacts, making it a target for modification. B) Chemical structure of 
Inhibitor 9 and a derivative designed to be inactive by substituting the nitrogen (red) in the 
piperazine side chain. 
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group of compounds with simple amine alterations that were amenable via the route of synthesis 
employed (Figure 4.2).  Compounds were designed with the assistance of Dr. Jian Jin (Center for 
Integrative Chemical Biology and Drug Discovery, UNC-Chapel Hill), and were synthesized by CDS. We 
characterized the newly synthesized analogues using the substrate p-nitrophenyl glucuronide (PNPG) by 
measuring absolute Ki values for each inhibitor against EcβG, equilibrium inhibition against each EcβG, 
SaβG, and CpβG, and equilibrium inhibition of β-glucuronidase activity in cultured E. coli cells (Table 
4.1).  Inhibitor 9, the parent compound, displayed low-nanomolar (EC50 = 5 nM) inhibition in E. coli 
cells, and each analogue maintained the same level of inhibition. Inhibitor 9-81 and Inhibitor 9-79 showed 
the greatest improvement (EC50 = 1.6 nM and EC50 = 2.6 nM, respectively). We saw improved Ki values 
across the board with 2- to 10-fold increased potency relative to Inhibitor 9 (Ki = 54 nM). Inhibitor 9-81 
(Ki = 4 nM) and Inhibitor 9-79 (Ki = 10 nM) were once again the most potent.  
  
 
 
Figure 4.2. Chemical structure of Inhibitor 9 and analogues designed from it to increase potency by 
substituting the morpholine side chain (red). 
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Inhibitor analogues maintained potent IC50 values against EcβG and SaβG compared to Inhibitor 
9. The largest improvement from these assays arose from IC50 values against CpβG, of which Inhibitor 9 
exhibited a 10-fold decrease in potency (IC50 = 72 nM) compared to EcβG and SaβG. This relative level 
of potency was maintained for each analogue, except for Inhibitor 9-79, which exhibited a 10-fold 
increase in potency (IC50 = 4.5 nM). Thus, Inhibitor 9-79 is attractive as a lead compound for this project 
because it shows nearly the highest potency observed to date in E. coli cell-based assays (EC50 = 2.6 nM) 
and the highest potency across the board with the purified β-glucuronidases in-hand, separating itself 
from its Inhibitor 9 analogue counterparts in CpβG IC50  assays.  CpβG is by far the least catalytically 
efficient enzyme studied as yet (see Table 2.2).  As such, it’s unclear that broad-spectrum potency for all 
bacterial β-glucuronidases will be essential for in vivo success, and future studies will be required to 
resolve that question. 
4.3.3 Crystal Structures of Inhibitor Analogues in Complex with EcβG 
 To better understand the structural basis of analogue efficacy, we sought to resolve the crystal 
structure of these compounds in complex with the tested enzymes. We successfully determined two 
structures of EcβG – complexes with Inhibitor 9-77 to 2.8 Å resolution and Inhibitor 9-79 to 2.3 Å 
resolution (Figure 4.3, Table 4.2). Each crystalized in space group C2 with two monomers in the 
asymmetric unit. One molecule of Inhibitor 9-77 was observed in the ligand binding pocket of the 
enzyme, adjacent to the catalytic sugar-binding pocket and in a mode analogous to all previously-
Table 4.1. Cell-based and in vitro inhibition of β-glucuronidase activity using PNPG as the substrate. 
Data are represented as the average (N = 3) ± SEM. 
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determined crystal structures of bacterial β-glucuronidase inhibitor complexes, including Inhibitor 9. 
Overlaying the active site with previously determined structures, including the un-liganded structures 
from SaβG and CpβG, the side chains of the catalytic glutamic acid residues and the ligand-binding 
tyrosines remain in the same positions regardless of the presence of the inhibitor analogue (Figure 4.4).  
  
 
 
 
 
 
Figure 4.3. Full length structures of EcβG in complex with Inhibitor 9-77 (A) and Inhibitor 9-79 (B). 
Pictured is the asymmetric unit each containing two EcβG monomers with one molecule of each 
inhibitor bound in the ligand-binding pocket of each monomer. 
 
 
Table 4.2. Crystallographic statistics of two structures of full-length EcβG in complex with Inhibitor 
9-77 and Inhibitor 9-79. 
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 The structure of Inhibitor 9-79 in complex with EcβG exhibited unique features relative to 
Inhibitor 9 and Inhibitor 9-77 complexes. The bound Inhibitor 9-79 produced incomplete electron density 
from the composite omit map outside of the core 4-ring scaffold (Figure 4.5). As seen in Figure 4.6, there 
was unsettled density on the bottom left and right of the 4-ring scaffold that could not be explained 
through a single ligand conformation. Thus, we built alternative conformations into the electron density, 
and upon refinement, the occupancies of each conformation bound to chain B plateaued at 0.54 and 0.42 
with average B-values of 86.73 and 87.72 Å
2
, respectively.  For comparison, the B-factors for Inhibitor 9 
and Inhibitor 9-77 were 88.85 and 47.62 Å
2
, respectively.  Inhibitor 9-79 is unique from the other 
members of this series because the morpholine side chain was substituted for a piperazine group that 
effectively duplicates the moiety previously determined to be critical for inhibition. Indeed, the two 
Figure 4.4. Overlay of ligand-binding pocket of EcβG in complex with Inhibitor 9-77 (A) And 
Inhibitor 9-79 (B) with previously determined structures of bacterial β-glucuronidases highlighting 
catalytic residues and flexible tyrosines. 
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binding orientations of Inhibitor 9-79 place each piperazine in the active site and in contact with the 
catalytic glutamic acid residues (Figure 4.4B).  These two orientations, which are unique to Inhibitor 9-
79, may explain the increase in potency in regards to CpβG, although structure-function-mutagenesis 
experiments would be required to adequately answer that question. 
 
 
 
4.3.4 Alleviation of CPT-11-Induced Diarrhea 
 We tested the lead compound, Inhibitor 9, in a model of drug-induced toxicity in mice. 
Specifically, groups of mice received either vehicle controls or a toxic dose of CPT-11 with or without 
pretreatment with Inhibitor 9 (Figure 4.6). The dosing scheme has been established in previous 
investigations (74). The mice that were pretreated with Inhibitor 9 developed significantly less toxic 
diarrhea by day 10 compared to the CPT-11-only group, indicating that Inhibitor 9 is effective at 
alleviating CPT-11-induced toxicity in mice. These experiments are currently being repeated with 
Inhibitor 9-79 in order to relate increased broad spectrum potency to in vivo efficacy. 
Figure 4.5. Orientation of Inhibitor 9-79 bound to EcβG. Unresolved density in the composite omit 
map (grey) was accounted for through multiple conformations. Map is contoured at 1.0 σ. 
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4.4 Discussion 
 We have described here the synthesis of inhibitor analogous, designed to increase potency for an 
already potent compound. Based on a previously determined structure of the parent compound in complex 
with CpβG (Figure 4.1), synthesis strategies revolved around the solvent-exposed morpholine group, 
altering the size and charge in an attempt to increase potency (Figure 4.2). With the exception of 
Inhibitor 9-80, where a piperidine group was substituted, each analogue saw an increase in potency 
irrespective of the measurement. Inhibitor 9-79 stood out from its counterpart analogues due to a 10-fold 
increase in potency as measured by the IC50 value against CpβG (Table 4.1).  
With the goal of better understanding the differences in the mechanism for inhibition, we 
successfully determined the x-ray crystal structures of EcβG in complex with Inhibitors 9-77 and 9-79 
(Figure 4.3). Inhibitor 9-77 bound in the same general location, in the ligand-binding pocket, as all 
previously determined structures of EcβG in complex with novel inhibitors. Importantly, Inhibitor 9-79 is 
unique in that it appears that the compound binds in two conformations, owing to its symmetric 
piperazine groups, the original of which had been previously shown to be critical for inhibition (Figure 
4.4). 
Figure 4.6. Mouse models of CPT-11-induced toxicity were employed to measure the therapeutic 
effects of Inhibitor 9. Groups of mice (N = 10) received either vehicle control or doses of CPT-11 
with or without pretreatment with Inhibitor 9. Incidences of bloody diarrhea were observed and 
measure throughout the experiment. ***, p < 0.001 
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Based on catalytic and inhibition data, it appears that there is an upper limit for inhibition for 
Inhibitor 9 and its analogues in the single-digit nanomolar range. Compared to EcβG and SaβG, CpβG 
has a 100- and 10-fold decrease in catalytic efficiency, respectively (see Chapter 3). Something in this 
lack of activity relative to faster GI bacterial enzymes, perhaps as a result of the loop composition, means 
that this panel of inhibitors cannot reach that upper limit while binding to CpβG, with the exception of 
Inhibitor 9-79. Thus, we hypothesize that the symmetry of Inhibitor 9-79 allows it to bind to CpβG in a 
way to produce inhibition with greater efficiency than its counterparts, and this advantage is not realized 
with EcβG and SaβG because the upper limit of inhibition has already been reached.  
 These synthesized analogues, to date, have displayed the greatest potency of any studied β-
glucuronidase inhibitors. As such, it will be necessary to continue the characterization of these 
compounds by analyzing their in vivo properties in preclinical models of drug-induced toxicity and 
efficacy. Studies of CPT-11-induced toxicity in mice show that Inhibitor 9 is among the most potent in 
vivo compound tested to-date (Figure 4.6). However, Inhibitor 9-79 has yet to be tested in preclinical 
models including pharmacokinetic and bioavailability analysis. Nonetheless, we hypothesize that, owing 
to its unique symmetry where it appears to effectively inhibit in two conformations, Inhibitor-9-79 would 
be a more effective broad-spectrum inhibitor of bacterial β-glucuronidases in vivo than previously studied 
compounds. And because we have already shown that broad-spectrum inhibition is relatively critical to in 
vivo success (see Chapter 3), Inhibitor 9-79 should display potent in vivo efficacy that could translate to 
the clinical setting.  
`  
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Chapter 5 
Identification of Bacterial β-Glucuronidase Inhibitors via High-Throughput Screening of a Large 
Chemical Diversity Library 
 
5.1 Summary 
 The toxicity of certain therapeutics has been linked to commensal bacterial β-glucuronidases, 
which cleave glucuronides from inactivated drug conjugates, allowing the reactivated drugs to then 
damage the gastrointestinal epithelium.  This mechanism has been substantiated for the anticancer drug 
CPT-11, which produces large intestinal damage and dose-limiting diarrhea, and for non-steroidal anti-
inflammatory drugs, which cause small intestinal ulcerations.  In both cases, initial small molecule hit 
compounds served as selective but non-lethal bacterial β-glucuronidase inhibitors that alleviated 
gastrointestinal damage.  Here, results from a high-throughput screen of a diverse 100,000 compound 
chemical library identify novel, chemically-distinct, potent and selective bacterial β-glucuronidase 
inhibitors.  Of the 379 hit compounds, 298 were validated with IC50 values less than 30 µM, and 19 
compounds displayed nanomolar inhibition. Five representative chemically-distinct compounds are 
shown to have no effect on the mammalian enzyme orthologue, to be non-lethal to bacterial or human 
cells, and effective against the enzyme target in cultured E. coli bacteria. These data broaden and deepen 
the understanding of the chemical and structural features capable of inhibiting this novel class of drug 
targets, the first to be identified in the mammalian microbiome.  
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5.2 Introduction 
Disrupting the delicate relationship between host and commensal bacteria can be significantly 
detrimental, in a manner conceptually similar to auto-immune disorders (1–4, 11, 107–109). One enzyme 
in particular, β-glucuronidase, expressed by intestinal symbiotic bacteria, plays a critical role in the 
enterohepatic circulation of endogenous and xenobiotic compounds marked for gastrointestinal (GI) 
excretion by glucuronide conjugation (110–112).  Furthermore, a range of drug toxicities mediated by 
symbiotic bacterial enzymes, including β-glucuronidase, pose serious health problems that are 
increasingly being appreciated (87, 90). In the GI tract, commensal β-glucuronidases remove the 
glucuronide sugar moiety, which is used by the bacteria as a carbon source, from circulated compounds 
and release the previously conjugated compound as an aglycone.  In the case of bilirubin, for example, 
this facilitates reabsorption and recirculation of this vital endobiotic (113).  However, this same pathway 
is now established in the development of dose-limiting diarrhea induced by the anti-cancer drug CPT-11 
(irinotecan)  (37–44).  
We have previously shown that the GI toxicity of CPT-11 can be alleviated by selectively 
inhibiting the symbiotic bacterial β-glucuronidases (74, 106) by identifying novel β-glucuronidase 
inhibitors that disrupt enzyme activity in viable bacterial cells with no apparent toxic effects. We further 
showed, using x-ray crystallography and biochemical assays, that the novel inhibitors bound to a loop 
unique to the bacterial β-glucuronidases and critical for inhibition, and thus, exerted no effect on 
mammalian β-glucuronidases.  Bacterial β-glucuronidases have been similarly implicated in NSAID-
induced toxicity of the small intestine, which is an increasingly appreciated side effect of these widely 
used therapeutics (82). Certain NSAIDs have been known to undergo the same metabolism through 
glucuronide drug conjugates, and although the cause of the toxicity remained elusive, we demonstrated 
that bacterial β-glucuronidase inhibitors alleviate the toxicity associated with the NSAIDs diclofenac, 
indomethacin, and ketoprofen (85, 86).  
Preliminary inhibitors were discovered using a relatively small, 10,000 compound chemical 
library screen (74, 106).  Here, we describe the results from a 10-fold larger high-throughput screen 
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(HTS) of a 100,000 compound chemical diversity set performed at the UNC Center for Integrative 
Chemical Biology and Drug Discovery (CICBDD). We identified and validated 379 compounds that 
inhibited purified E. coli β-glucuronidase. Compounds representative of five structurally-diverse regions 
of chemical space were selected for in vitro and cell-based characterization.   
 
5.3 Materials and Methods 
HTS Reagents 
 The assay substrate 4-nitrophenyl β-D-glucuronide (PNPG) and bovine liver β-glucuronidase 
were purchased from Sigma-Aldrich (St. Louis, MO), and control initial Inhibitor 1 was purchased from 
Asinex, Inc. (Winston-Salem, NC). The expression and purification of E. coli β-glucuronidase (EcβG), 
and the performance of the in vitro and cell-based assays, were conducted as described previously (74, 
106).   
LOPAC Compound Collection  
The Library of Pharmacologically Active Compounds (LOPAC) was purchased from Sigma-
Aldrich as 1 mM stocks in dimethyl sulfoxide (DMSO). The library was previously prepared as 1 μL 
samples in 384-well V-bottom polypropylene microplates (Greiner, Monroe, NC), sealed by an ALPS 
3000 microplate heat sealer (Thermo Fisher Scientific, Hudson, NH) and stored at 
−
20°C. On the day of 
use, the compounds were thawed and diluted to 50 μM (5x final concentration) in reaction buffer (20 mM 
HEPES, 50 mM NaCl, pH 7.4) over two steps using a Thermo Scientific MultidropCombi Reagent 
Dispenser (Waltham, MA) and Multimek NSX-1536 assay workstation system fitted with a 384-well 
head (Nanoscreen, Charleston, SC). Finally, 1 μL of this stock was spotted into the wells of a 384-well 
black PerkinElmer Proxiplate (Waltham, MA) for assay use, as described below.   
100K Diversity Screening Compound Collection  
The 100K Diversity Collection of screening compounds was selected from the Enamine’s HTS 
collection (enamine.net) based on diversity and drug-likeness criteria. Murcko scaffolds were used for the 
diversity selection (114). Essentially, a compound's Murcko scaffold includes contiguous ring systems 
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plus chains that link two or more rings. These scaffolds may be used to group compounds of a large 
collection into clusters, in each of which the compounds share the same Murcko scaffold. Here, for each 
Murcko cluster, at most 20 compounds were randomly selected in order to maximize the scaffold 
diversity of the 100K screening collection. Compounds were also filtered to eliminate reactive functional 
groups (REOS score > 
−
2) (115) and include compounds that obey the “rule of five” (116) with slight 
deviations to permit slightly larger and more lipophilic compounds. Based on the above selection process, 
a set of 100,000 compounds was purchased from Enamine Ltd (Kiev, Ukraine). The compound collection 
plates were prepared by resuspending the powder stock to 1 mM in DMSO in barcoded glass vials with 
sonication using a Covaris S2 (Covaris, Woburn, MA). Compounds were plated at 1 mM in 100% DMSO 
in 384-well V-bottom polypropylene microplates using a Tecan Genesis 200 (Münnedorf, Switzerland). A 
Multimek spotted 1 μL of the 1 mM compounds into 384-well V-bottom polypropylene microplates and 
plates were heat-sealed and stored at 
−
20 °C.  
HTS Assay 
 The diversity library plates (1 mM in 100% DMSO and a volume of 1 µL as described above) 
were removed from 
−
20 
o
C freezers and allowed to reach room temperature. Each compound plate was 
diluted 1:20 in enzyme buffer (20 mM HEPES, 50 mM NaCl, pH 7.4) to a concentration of 50 µM (20 µl 
final volume) using a Multidrop dispenser. Control solutions were prepared in a separate 384-well plate 
consisting of the negative (20 mM HEPES, 50 mM NaCl, 5% DMSO, pH 7.4) and positive (20 mM 
HEPES, 50 mM NaCl, 5% DMSO, 0.2 M sodium carbonate, pH 7.4) control buffers, as well as a known 
β-glucuronidase inhibitor (Inhibitor 1) at two concentrations that produce approximately 50% and 100% 
inhibition diluted to 5% DMSO in enzyme buffer. The enzymatic reaction used in the HTS consisted of 
three addition steps. The first step consisted of the addition of 5 µl of diluted diversity library compounds 
and controls using the Multimek into an assay plate. This process was repeated for all of the assay plates. 
A Multidrop dispenser then added 10 µL of purified E. coli β-glucuronidase (20 mM HEPES, 50 mM 
NaCl, 3.75 nM E. coli β-glucuronidase, 0.15% BSA, pH 7.4). The plates were incubated for 10 minutes to 
allow for proper binding between the compound and the enzyme. A second Multidrop dispenser then 
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initiated the reaction with the addition 10 µL of substrate (20 mM HEPES, 50 mM NaCl, 0.4 mM PNPG, 
0.1% BSA, pH 7.4). The plates were then immediately transferred to an EnVision Multilabel Reader 
(PerkinElmer) and the absorbance was measured at 405 nm at one minute intervals over the initial 10 
minute period, corresponding to enzymatic production of 4-nitrophenol.  
Compounds for dose–response curves were resuspended to a concentration of 10 mM in DMSO. 
The HTS hits were transferred into 384-well V-bottom polypropylene microplates and diluted as 3-fold 
dilutions over 10 points using the Tecan. Compound titration series of all hits for IC50 evaluation were 
then spotted at 1 µL by the Multimek into 384-well V-bottom microplates and diluted 20-fold in enzyme 
buffer using a Multidrop dispenser. The diluted titrations were then spotted at 1 µL into 384-well black 
Proxiplates in triplicate, and reagents were added to initiate the assay as described above. The final top 
concentration of dose–response curves was 10 µM compound (1% DMSO).  
Data Analysis 
 Screening data were processed using ScreenAble software (Screenable Solutions, Chapel Hill, 
NC). The percent inhibition was determined on a plate-to-plate basis by comparing the rate of product 
formation for the compound versus the negative controls.   
During assay development and validation, the Z’ factor was calculated for each assay plate to assess the 
quality and robustness of the HTS. The Z’ factor was determined using the following formula: 
     (
3σmax  3σmin
|μmax   μmin|
) 
where σmax and σmin are standard deviations (SDs) in respective plate maximum and minimum signal 
controls, and μmax and μmin are the plate-averages of the respective controls, as defined above. 
 During HTS, trimmed Z factors were calculated using the same controls and formula but using a 
MIDMEAN calculation (R v2.1.5) to determine control well averages.   
 Compound IC50 values were calculated by first converting the rate of product formation to 
percent inhibition with respect to on-plate controls and then fitting the percent inhibition values to curve 
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equations using ScreenAble. The IC50 values of the representative selection hits and Kinase Focus Set hits 
were calculated using ScreenAble with a 3- or 4-parameter curve fit. 
Hit Analysis 
 379 hit compounds from the 100K Diversity Collection were grouped into homogeneous clusters, 
in which the similarity between any two compounds was at least 65% according to the Tanimoto metrics 
with ECFP4 fingerprints (Pipeline Pilot, ver 7.5; Accelrys Software, Inc.; 2009). The clustering procedure 
revealed 37 clusters (of more than 3 compounds) and 85 individual compounds. Only compounds with 
validated IC50 values less than 2 µM were considered for further evaluation. Compounds from the largest 
clusters, as well as compounds from individual or 2-hit clusters, were selected to provide a diverse group 
of compounds in order to build more diverse structure-activity relationships (SAR).  
In vitro Assays 
The β-glucuronidases from Streptococcus agalactiae (SaβG) and Clostridium perfringens (CpβG) 
were expressed and purified as described (74, 106). Inhibition assays using these enzymes, in addition to 
EcβG, were conducted by measuring the β-glucuronidase-catalyzed conversion of PNPG to 4-nitrophenol. 
Reactions were conducted in 96-well, clear-bottom assay plates (Costar, Tewksbury, MA) at 37 
o
C in 50 
µL of total volume. The reaction consisted of 10 µL of assay buffer (100 mM HEPES, 250 mM NaCl, pH 
7.4), 5 µL of inhibitor (various concentrations), 5 µL of 10 nM enzyme, and 30 µL of substrate (200 µM 
final).  The reaction was incubated at 37 
o
C for 6 hours to allow the reaction to reach equilibrium and then 
quenched with 100 µL 0.2 M sodium carbonate. The product formation was measured using a PHERAstar 
Plus microplate reader (BMG Labtech, Ortenberg, Germany). The acquired data were analyzed using 
Microsoft Excel and Sigmaplot 11.0. The percent inhibition for each concentration was calculated based 
on changes in absorbance versus zero-inhibitor controls and used to plot a dose-response curve. The IC50 
value was calculated as the concentration that produced 50% in vitro inhibition.  The same assay was 
performed with purified bovine liver β-glucuronidase with PNPG as the substrate. 
We also tested the ability of these compounds to inhibit β-glucuronidase activity in E. coli cells. 
We grew HB101 E. coli cells, transformed with the pET-28a vector containing the β-glucuronidase gene, 
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to an OD600 of 0.6 in LB medium and used a small aliquot in an assay similar to the in vitro IC50 assay 
described above. The cells (39 µL) were incubated with 1 µL of variable concentrations of inhibitor and 
10 µL of 1 mM PNPG at 37 
o
C for 6 hours. The reaction was quenched with 100 µL 0.2 M sodium 
carbonate. The amount of substrate turnover and therefore the amount of inhibition is calculated from the 
change in absorbance compared to zero-inhibitor controls. EC50 values were calculated as the amount of 
compound necessary to produce 50% inhibition.   
Toxicity of Inhibitors Toward Cultured Cells 
The toxicity of inhibitors to bacterial cells was examined by incubating HB101 E. coli cells, 
transformed with the pET-28a vector containing the β-glucuronidase gene,  grown to an OD600 of 0.6 in 
LB medium with each compound, as well as DMSO and ampicillin as controls, for 6 hours. Cell 
survivability was measured by plating a 10
-5
 dilution of the cells on LB media enriched with kanamycin. 
After overnight incubation, colonies were counted to quantify cell viability.   
 
5.4 Results 
5.4.1 HTS Assay Conditions 
We have previously described several assays with purified E. coli β-glucuronidase (EcβG)  to 
assess the potential inhibitory capacity of small molecule compounds (74).  For the high-throughput 
screen (HTS), 4-nitrophenyl β-D-glucuronide (PNPG) was used as the assay substrate; the products of its 
hydrolysis by β-glucuronidase are the glucuronic acid sugar and 4-nitrophenol, which readily absorbs at 
405 nm (Figure 5.1A). Because some of the compounds in the diversity library also absorb at this 
wavelength, we measured the initial linear rate of change in absorbance in the HTS reaction. Therefore, a 
significantly decreased rate of product formation relative to negative controls indicated a positive hit, and 
the change in the rate of product formation, as a percent of the negative controls, was used to quantify the 
amount of inhibition.  
Purified EcβG was validated for its use in this HTS by maintaining activity at room temperature 
for 6 hours (Figure 5.1B). The enzyme’s tolerance to DMSO, in which the diversity library compounds 
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are dissolved, was also tested. Past experiments have indicated that DMSO will denature bacterial β-
glucuronidase (117); indeed, we found a significant decrease in activity after a 15 minute incubation in 
1% DMSO. However, this effect can be prevented with the addition of bovine serum albumin (BSA) 
(Figure 5.1C). EcβG maintains its activity in up to 5% DMSO in the presence of 0.1% BSA (Figure 
5.1D). As such, we added BSA to the enzyme and substrate stocks during the screen (to a 0.1% BSA final 
concentration) to preserve consistent enzyme activity. 
 
 
 
 
The KM of PNPG was determined experimentally to be 0.16 mM (data not shown). Therefore, we 
titrated the enzyme to the KM concentration, and chose the initial 10 minute period for data collection 
because it demonstrated a linear and robust rate of 4-nitrophenol production. Finally, we found that the 
reaction could be quenched with the addition of sodium carbonate. Ultimately, the concentrations for the 
HTS reaction were 1.5 nM EcβG, 0.1% BSA, and 0.16 mM PNPG; each component was diluted in 
Figure 5.1. (A) Reaction utilized for HTS assay. (B) Temperature effects on EcβG in the HTS assay. 
Data are presented as ± SD. (C) Addition of BSA to the HTS assay improves EcβG activity. Data are 
presented as ± SD. (D) DMSO tolerance of EcβG in the HTS assay. Data are presented as ± SD. 
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enzyme buffer (20 mM HEPES, 50 mM NaCl, pH 7.4). The reaction was validated in 384-well microplate 
format, with a final reaction volume of 25 µL.  
5.4.2 HTS Assay 
The HTS reaction was initiated by the addition of substrate to solutions containing buffer, 
compounds and enzyme, and the increase in absorbance at 405 nm was measured over the initial 10 
minutes (Figure 5.2A). Negative controls consisted of DMSO in the initial buffer in place of the 
compounds. The reaction was quenched for the positive control wells with the addition of 3.4 M sodium 
carbonate to the initial buffer addition. Each plate also consisted of “standard” control reactions using one 
previously discovered putative inhibitor, Inhibitor 1, at two concentrations that would produce 100% and 
approximately 50% inhibition in order to ensure operational consistency during the screen. The diversity 
library was screened at a final concentration of 10 µM, corresponding to a final DMSO concentration of 
1%. The HTS reaction was initially tested for day-to-day operational consistency and maintained Z-
factors around 0.8 (data not shown). Initial compounds from the Library of Pharmacologically Active 
Compounds (LOPAC) screened in duplicate displayed very good reproducibility with a low false-positive 
rate (Figure 5.2B).  
During the screen, each plate maintained trimmed Z factors greater than 0.8, with only a few 
exceptions (Figure 5.2C). The screen produced 405 hits with greater than 45% inhibition (Figure 5.2D). 
This list was narrowed to 379 compounds using drug-likeness filtering. All 379 hits were examined in full 
dose-response curves using the HTS assay. Of those hits, 298 compounds were validated with IC50 values 
less than 30 µM, and 19 compounds displayed nanomolar inhibition. From these data, we selected a group 
of potent (IC50 < 1.5 µM), chemically distinct compounds for further evaluation.  
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5.4.3 Representative Compound Characterization 
From the 298 validated hits with IC50 values less than 30 µM, we established 37 chemically-
related clusters that contain 3 or more compounds and left 85 individual compounds.  At this point, 
chemicals representative of five structurally-diverse regions of chemical space were selected for complete 
in vitro and cell-based characterization (Figure 5.3). The five representative compounds, termed 
Inhibitors C, M, N, O and P, range from 297 to 420 Da in size, and contain from one (Inhibitor C) to four 
(Inhibitor O) conjugated rings with intervening polar linkages.  Furthermore, they are representative of a 
range of chemical clustering results from the full HTS screen, from singletons (Inhibitor C), to small 2-
compound clusters (Inhibitors M, O, and P), and up to a larger 16-compound cluster (Inhibitor N).  For 
further characterization, each compound was first confirmed to be selective for inhibiting bacterial β-
Figure 5.2. (A) HTS assay procedure. (B) Operational consistency of the HTS assay using 
preliminary LOPAC library. Inhibition values from duplicate runs are compared on the x and y axes. 
(C) Z-factors for each HTS plate. (D) For the complete 100,000 diversity library, the number of 
compounds (samples) observed for bins of percent inhibition; arrow indicates where the small 
number of effective hits was found. 
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glucuronidase versus bovine liver β-glucuronidase, a representative mammalian enzyme orthologue, at up 
to 370 µM inhibitor concentrations (Figure 5.4A). Compounds were also found to be non-toxic to 
cultured mammalian HEK293T cells at 100 µM concentrations for 24 hours (data not shown), or to 
cultured E. coli cells at the same concentrations (Figure 5.4B). Thus, these representative hits are 
selectively capable of inhibiting bacterial β-glucuronidases, and appear non-toxic to either bacterial or 
mammalian cells.  
 
 
 
  
Figure 5.3. Chemical structures of five hits pursued for further analysis, along with the size of the 
clusters of associated hits from the full HTS. 
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The five representative novel inhibitors were examined for their ability to inhibit purified 
bacterial β-glucuronidases in vitro, as well as for their efficacy against the enzyme target in cultured E. 
coli cells. Compounds were measured for their ability to inhibit EcβG in vitro. Measured Ki values 
against EcβG were comparable, ranging from 220 to 570 nM for Inhibitor P and Inhibitor N, respectively. 
β-glucuronidases from the GI-associated commensals Clostridium perfringens (CpβG) and Streptococcus 
agalactiae (SaβG) were purified, and IC50 values were measured for each compound against those 
enzymes in addition to EcβG.  Each proved to be inhibitors of EcβG, with IC50 values ranging from 130 
nM (Inhibitor O) to 2.2 µM (Inhibitor N), but IC50 values varied with the other purified enzymes (Table 
5.1). No inhibition was observed for Inhibitor N against CpβG and SaβG, and Inhibitors C and M were 
between 3- and 30-fold less active against CpβG and SaβG relative to EcβG. Furthermore, Inhibitors M 
and P were 10- and 30-fold more potent, respectively, against SaβG compared to CpβG, while Inhibitor O 
was 5-fold more potent for the CpβG compared to SaβG.  Only Inhibitor O maintained sub-micromolar 
inhibition against all three β-glucuronidase orthologues. Finally, each compound was validated in an E. 
coli cell-based assay and proved to be effective inhibitors with EC50 values ranging from 12 nM (Inhibitor 
C) to 1.4 µM (Inhibitor M). Inhibitor O was the second most potent compound at 130 nM. Thus, several 
Figure 5.4. (A) Inhibition properties of hits against a representative mammalian β-glucuronidase, 
from bovine liver. (B) Hits do not kill cultured E. coli cells at 100 µM concentrations; ampicillin at 
10 nM is used as a positive control, and the LB-only group is used to calculate the percent survival. 
Data are presented as ± SEM. 
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novel non-lethal inhibitors selective for bacterial β-glucuronidases were validated to be potent and 
effective in living bacteria against this drug target in the mammalian microbiome. 
 
 
 
5.5 Discussion 
 The link between β-glucuronidase expressed by symbiotic GI-associated microbiota and dose-
limiting toxicity caused by CPT-11 and NSAID treatments has been previously established (62, 74, 82, 
85–87, 90, 106, 118).  Indeed, using novel inhibitors, we have recently demonstrated that selective 
inhibition of bacterial β-glucuronidase in mice will alleviate the toxic diarrhea caused by CPT-11 
treatment, as well as small intestinal ulcerations as a side effect of treatment with a variety of NSAIDs 
(74, 85, 86, 106). In this report, we screened a library of small molecule compounds with the goal of 
understanding the chemical and structural bases for bacterial β-glucuronidase inhibition. Five 
representative chemically-diverse compounds were validated, chosen for further evaluation, and were 
found to have the characteristics we consider important for in vivo use:  potency both in vitro and in cells, 
selectivity for the bacterial enzymes and not the mammalian orthologue, and non-lethality to bacterial and 
mammalian cells.  
Because we have utilized two newly purified GI-associated bacterial β-glucuronidases, we 
provide novel information on the structural basis for inhibitor activity across distinct microbial enzymes, 
as discussed below.  The GI tract is composed of the Proteobacteria (e.g., E. coli), the Firmicutes (e.g., S. 
agalactiae, C. perfringens) and the Bacteroidetes (e.g., Bacteroides fragilis) phyla of bacteria.  In this 
work, we examine representatives of the Proteobacteria and the Firmicute β-glucuronidases and show that 
Table 5.1. Cell-based and in vitro inhibition of β-glucuronidase activity.  
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there is dissimilarity to the inhibition profiles observed. For example, Inhibitor N shows no impact on the 
Firmicute proteins but is effective against the representative Proteobacteria enzyme from E. coli. 
Although the enzymes studied in this report show a high degree of structural similarity, there are key 
deviations in two loop regions adjacent to the ligand binding site. In general, clearly, more work is 
required to examine a larger number of the Proteobacteria and Firmicute enzymes, as well as the 
characterization of Bacteroidetes proteins expected to perform this function. 
Nevertheless, the data presented here are useful even at this early stage of understanding the 
enzyme orthologues present in the GI microbiota. SaβG that was examined for inhibition by the five 
representative compounds shares 41% identity to EcβG.  By alignment, it contains an asparagine residue 
at the position equivalent to G364 and M365 in EcβG and CpβG, respectively, and a methionine 
corresponding to F450 and M448, respectively, in the other two proteins.  Thus, SaβG would appear to be 
intermediate between EcβG and CpβG with respect to these two positions suggested to be important in 
inhibitor efficacy.  For example, the polarity of the SaβG N residue equivalent to M365 in CpβG perhaps 
allows the Inhibitor M compound improved ability to bind to SaβG, as this inhibitor is 10-fold more 
effective toward this target orthologue (Table 5.1).  
Taken together, these data provide a framework for predicting potential efficacy against β-
glucuronidases from other commensal bacterial strains across the GI-associated microbiota in order to 
successfully and completely alleviate toxic, drug-induced GI side effects. Such information will be 
important not only in designing more effective therapeutics, but also in understanding the potential impact 
of such targeted reagents on drug toxicity and efficacy, as well as on endobiotic and xenobiotic 
homeostasis involving glucuronide-dependent enterohepatic circulation. 
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Chapter 6 
Conclusions and Further Work 
 
6.1 Chemical Modification of Lead Compounds 
 Crystallographic analysis of bacterial β-glucuronidases in complex with our novel inhibitors has 
demonstrated that each molecule binds in essentially the same location at the mouth of the active site. 
Based on the structure of E. coli β-glucuronidase (EcβG) in complex with glucaro-δ-lactam (GDL), an 
analogue of glucuronic acid, we believe that the glucuronide moiety generally binds further into the active 
site gorge, adjacent to the catalytic glutamic acid residues (Figure 6.1). Therefore, one can envision new 
compounds based on the existing scaffolds of potent compounds with the addition of a GDL-type moiety 
to allow for more extensive binding in the β-glucuronidase active site. Previously determined structures 
facilitate the addition of the glucuronide group to the proper location on the inhibitor. Figure 6.1 outlines 
the potential for such a combined inhibitor. It overlays the Inhibitor 9-bound structure of C. perfringens 
β-glucuronidase (CpβG) with the EcβG structure in complex with GDL, highlighting that the ligands 
generally populate two separate areas in the active site. Although as it appears the ligands are too close 
together for proper binding, these bacterial β-glucuronidases have proven promiscuous and flexible as 
evidenced by the diversity of putative inhibitors. Thus, a combined inhibitor would still be effective and 
would ideally show increased potency by increasing the hydrogen bonding interactions between ligand 
and protein.  
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6.2 Bacteroides β-Glucuronidase 
 Metagenomic analysis identified two distinct genes responsible for β-glucuronidase activity (28). 
These genes, termed gus and BG, belong to distinct phyla of bacteria. The phyla Firmicutes and 
Proteobacterium contain the gus gene, while the Bacteroidetes phylum contains the BG gene. In this 
work, only proteins expressed from putative gus genes have been characterized. The BG-type enzymes 
share 21-25% identity to EcβG and appear to contain a shorter, 5-8 residue, bacterial loop based on 
sequence alignments (Figure 6.2). BG-type enzymes can be considerably longer (~900 residues) 
compared to gus-type enzymes (~600 residues). Although cultured Bacteroides bacteria have been shown 
to have considerably less β-glucuronidase activity than their Firmicute counterparts, Bacteroides are 
known to populate a much larger percentage of the mammalian gastrointestinal (GI) tract. Thus, their 
relative contribution to overall GI β-glucuronidase activity should be similar. Additionally, Wallace et al. 
demonstrated that our inhibitors are effective in cultured Bacteroides bacteria (74). Contrary to gus-type 
enzymes described here, the in vitro structure and function of BG-type β-glucuronidases has not been 
characterized.  
Figure 6.1. Overlay of CpβG (yellow) in complex with Inhibitor 9 (purple) and GDL (cyan) bound 
to EcβG (not pictured) 
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 For the system of β-glucuronidase inhibition to have in vivo success, we likely have to eliminate 
as much GI β-glucuronidase activity as possible. This would include the contribution of Bacteroides and 
thus, BG-type enzymes. Future work would include the expression and purification of putative β-
glucuronidases from Bacteroides sources. In addition to the in vitro characterization of their kinetic 
properties, we would seek to determine the structural basis of their activity relative to gus-type enzymes 
already studied through x-ray crystallographic analysis. Mutagenesis studies would clarify the 
mechanisms for probable differences in activity. Any activity would be measured in the presence of lead 
compounds, and those compounds that prove effective will become more promising leads.  
   
6.3 In vivo Mouse Studies 
 Analogous to studies performed with Inhibitor 1 outlined in Chapter 3, we wish to extend the in 
vivo results to additional lead compounds. For example, Inhibitor O (see Chapter 5) displayed potent in 
vitro and in-cell inhibition of E. coli. Distinguishing itself from its counterparts, Inhibitor O maintained in 
vitro potency against other GI-associated enzymes from C. perfringens and S. agalactiae. Inhibitor 5 (see 
Chapter 2) also maintained potency across all species and has already proved effective in alleviating CPT-
11-induced diarrhea. The most promising compounds, however, belong to the class of analogues of 
Inhibitor 9 (see Chapter 4). Although each of these compounds display more promising characteristics 
than the other compounds described in this work, Inhibitor 9-79 distinguishes itself by exhibiting 10-fold 
greater potency relative to other Inhibitor 9 analogues in CpβG IC50 assays.   
Figure 6.2. Sequence alignment of the putative “bacterial loop” region from E. coli compared to 
regions from various Bacteroides species. 
 
 
83 
 In addition to repeating experiments with new and more promising lead compounds, including 
complete pharmacokinetic analysis and oral availability, we would like to extend the characterization of 
these compounds. New experiments would include the analysis of effects on the pharmacokinetic profile 
of CPT-11 and NSAIDs beyond systemic circulation and into key organ locations, including liver and 
feces, including effects on the formulation and administration schedule of lead compounds.  Importantly, 
we would also like to illuminate effects on the anti-tumor efficacy of CPT-11 in a model that recapitulates 
the clinical setting. To do this, tumors would be grown in mice, as opposed to the experiment presented in 
Chapter 3 where tumors were xenografted. Mice would also be subjected to a dosing regimen that is 
comparable to the regimen performed in the clinic.  
 This work also does not include analysis on possible effects on GI-associated microbiota. Thus, 
we would like to perform 16S rRNA sequencing on the microbiota in mice, particularly focusing on GI-
associated species, before and after treatment with toxic drugs, such as CPT-11 and various NSAIDs, to 
quantify potential changes in the relative abundance of the bacterial species. Additionally, we would 
probe, via RNA-Seq experiments, significant changes in the expression of particular genes in the 
microbiome based on treatments with toxic drugs and the inhibitors presented here. Such experiments 
would help clarify potential side effects of selective microbial β-glucuronidase inhibition in vivo. 
 
6.4 New Models of GI Toxicity 
 Glucuronidation is a common pathway through which xenobiotic and endobiotic compounds are 
detoxified. This includes many classes of drugs that contain nucleophilic functional centers (16). By 
connecting these drugs with drugs that induce GI toxicity, we can search for new models of toxicity that 
may be alleviated through microbial β-glucuronidase inhibition. One such class of anti-cancer drugs 
includes topotecan (hycamtin), vorinostat (zolinza), idarubicin (idamycin) and epirubicin (ellence).  
Continued development of effective, targeted β-glucuronidase inhibitors may improve the tolerance and 
efficacy of these anticancer drugs.  Additionally, it is well established that the active metabolite of 
morphine is morphine-6-glucuronide, so β-glucuronidase inhibitors may strengthen the efficacy of 
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morphine by increasing systemic levels of morphine-6-glucuronide. Of course, care must also be taken to 
avoid a potential toxic buildup of this active metabolite. 
As outlined in Chapter 1, GI β-glucuronidases, in addition to familial glycoside hydrolases, play a 
critical role in homeostasis, particularly in regulating a healthy concentration of hormones or other 
endobiotics. Polymorphisms in such enzymes have been linked to serious if not fatal disorders. As such, 
deficiencies in glucuronide-conjugating metabolic reactions that result in an abundance of aglycones 
could be ameliorated through the use of microbial β-glucuronidase inhibitors, a main source of 
endogenous aglycone metabolites. It is also possible that the β-glucuronidase-targeted compounds could 
treat dark-pigment gallstones, which are created from reactivated bilirubin-glucuronide metabolites.  With 
the progressive societal need for new and effective therapies, challenges of drug-induced toxicity will 
likely continue to emerge, and thus, the possibilities are literally endless. 
 
6.5 Conclusions 
 Presented here is a system of specific, non-toxic bacterial β-glucuronidase inhibition that 
produces in vivo efficacy. From an initial high-throughput screen, we discovered the first set of novel 
inhibitors that were characterized structurally and biochemically and proved effective in models of drug-
induced toxicity in mice. We expanded the search to a larger, more comprehensive screen that expanded 
our knowledge of the structure-activity relationship between the inhibitors and their target, bacterial β-
glucuronidase. We delved deeper into creating a more promising clinical candidate by making chemical 
modifications to lead compounds, Inhibitor 1 and Inhibitor 9, to create superior in vitro potency and in 
vivo efficacy. Although we were successful in reducing bioavailability of Inhibitor 1 through analogue 
synthesis, the attempt to improve in vivo efficacy in models of toxicity was thwarted potentially by a lack 
of inhibition against a panel of bacterial β-glucuronidases purified from GI-associated species, 
Streptococcus agalactiae and Clostridium perfringens. Nonetheless, those results could prove useful in 
future endeavors. The most potent in vitro compound, Inhibitor 9, was improved in in vitro assays 
through chemical modification to a solvent-exposed side chain. The newly synthesized analogue, 
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Inhibitor 9-79, separated itself by maintaining low-nanomolar inhibition against each species of β-
glucuronidase while Inhibitor 9 and the other synthesized analogues displayed 10-fold reduced potency in 
CpβG IC50 assays. Further in vivo studies will be conducted to fully understand how these improvements 
translate to the preclinical setting. 
We are working to improve clinical outcomes for patients that are debilitated by drug-induced GI 
toxicity. The unique approach begun here could become a co-therapy to a range of chemotherapeutic 
regimens, similar to the use of xofran (ondansetron) for upper GI toxicity and nausea. It is nonetheless the 
start towards the emergence of a range of therapeutic targets, those from microbial sources, that have 
previously been overlooked. The selective inhibition of enzymes in the microbial cells that make up 90% 
of all cells in the human body, if validated, has the potential to not only establish a new drug discovery 
paradigm, but also improve the treatment of cancer, pain and other maladies. 
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Appendix A 
Structural Analysis of Mutant hCE1m6 
 
The lab of Dr. Phil Potter has synthesized a mutant form of human carboxylesterase 1 (hCE1), a 
promiscuous enzyme found through mammalian tissues, with the goal of processing CPT-11 to SN-38 
more quickly. This modified enzyme would be used as an enzyme/prodrug therapy to increase the amount 
of active metabolite that could reach the tumor site. The marker for successful mutations was the activity 
of rabbit carboxylesterase (rCE), which processes CPT-11 at 41 pmol/h/mg. In the same assay, wild-type 
hCE1 displayed no detectable CPT-11-converting activity. Therapy with rCE, however, would produce a 
harmful immunogenic reaction in humans while a modified human enzyme may overcome this concern. 
In Wierdl et al. from 2008, they created one particular mutant, termed hCE1-m6, that maintained levels of 
carboxylesterase activity relative to wild-type while producing improved CPT-11-converting activity 
levels, 40.5 pmol/h/mg, similar to rCE1. The mutant enzyme contained 7 point mutations from wild-type 
hCE1: M363L, L364M, K459R, F488Y, Q449R, L357I, S365G, Q361 insertion (119).  
 Our lab successfully determined the 2.8 Å un-liganded crystal structure of hCE1-m6 (Figure 
A.1). The protein was crystallized in the presence of SN-38, but no discernible ligand density was 
observed beyond glycosylation that was also observed in previous hCE1 structures. The mutated residues 
fit within the active site in well-defined electron density. By overlaying the hCE1-m6 structure with 
known structures from hCE1 (bound to tacrine) and rCE, we see a high degree of structural conservation 
throughout (Figure A.2) (120, 121). In fact, there were no discernible structural alterations in the active 
site. The main differences occurred in solvent-exposed loops (Figure A.3). These changes allow for 
changes in the active gorge. Viewed as a surface representation, we see that hCE1-m6 allows for less 
access to the catalytic serine (Figure A.4). Paradoxically, less space in the active site gorge may allow for 
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more substrate specificity. For CPT-11, for example, a smaller gorge may allow for tighter binding and 
thus, a higher catalytic efficiency. Docking CPT-11 onto the crystal structures of hCE1 and hCE1-m6, we 
see that there is still sufficient space for binding (Figure A.5). 
 
 
 
Figure A.1. Crystal structure of full-length hCE1m6 
(cyan). 
 
 
Figure A.2. Overlay of hCE1m6 (cyan) with previously determined structures of rCE (green) and 
hCE1 bound to tacrine (magenta). 
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Figure A.3. Overlay of hCE1m6 (cyan) with rCE (green) and hCE1 bound to tacrine (magenta) 
highlighting differences in solvent-exposed loops (red boxes). 
 
 
Figure A.4. Differences in the surface area of the catalytic gorge for hCE1m6 (cyan) and hCE1 
bound to tacrine (magenta) highlighting access to the catalytic serine residue (green). 
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Figure A.5. Docking of CPT-11 in the catalytic gorge for hCE1m6 (cyan) and hCE1 bound to 
tacrine (magenta) highlighting access to the catalytic serine residue (green). 
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Appendix B 
Immobilization of Active Human Carboxylesterase 1 in Biomimetic Silica Nanoparticles
2
 
 
Summary 
The encapsulation of proteins in biomimetic silica has recently been shown to successfully 
maintain enzymes in their active state. Organophosphate (OP) compounds are employed as pesticides as 
well as potent chemical warfare nerve agents. Thus, we sought to generate silica-encapsulated enzymes 
capable of responding to OPs.  We present the silica encapsulation of human drug metabolism enzyme 
carboxylesterase 1 (hCE1) in the presence of a range of catalysts.  hCE1 was successfully encapsulated 
into silica particles when lysozyme or the peptide R5 were used as catalysts; in contrast, 
polyethyleneimine (PEI), a catalyst employed to encapsulate other enzymes, did not facilitate hCE1 
entrapment. hCE1 silica particles in a column chromatography format detect the presence of the OP 
pesticides paraoxon and dimethyl-p-nitrophenyl phosphate in solution. These results may lead to novel 
approaches to detect OP pesticides or other weaponized agents, which are known to bind to hCE1. 
Indeed, we show that hCE1 silicate particles in a column chromatography format detect the presence of 
the OP pesticides paraoxon and dimethyl-p-nitrophenyl phosphate in solution. 
  
                                                 
2
Adapted from Edwards JS et al. (2011) Immobilization of active human carboxylesterase 1 in 
biomimetic silica nanoparticles. Biotechnol Prog 27:863–869.  
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Introduction 
 
 Sol-gel and biomimetic reactions have facilitated the use of immobilized enzymes in a range of 
applications (122). For example, several recent studies have employed the biomineralization of silica to 
encapsulate a variety of enzymes. This reaction occurs rapidly at room temperature using a source of 
silica, such as tetramethylorthosilicate (TMOS), and a polycationic catalyst to promote silica formation 
around the target enzyme.  Proteins encapsulated using this approach can be used to catalyze highly 
specific reactions, screen for enzyme inhibitors, or detect the presence of chemical compounds. Indeed, 
silica particles containing enzymes have been employed in biosensing applications, including microfluidic 
devices and aerosol detectors (123, 124).  
There are several advantages to using silica particles for encapsulation. The mild reaction 
conditions promote the capture of active enzymes and, in some systems, have been shown to increase 
enzyme stability (125). The simplicity and speed of the reaction also allow for rapid encapsulation and the 
cost-effective production of the particles for various needs. However, encapsulation efficiency varies with 
the catalyst-enzyme pair (126). Thus, optimal encapsulation conditions must be identified for each 
enzyme.  
 One promising application of encapsulated protein is the detection of chemical toxins, such as 
organophosphates (OP).  OPs are employed as agricultural pesticides, but have also been weaponized for 
use as highly toxic nerve agents e.g. sarin, soman, and cyclosarin (127, 128).  OP toxicity arises from the 
inhibition of acetylcholinesterase (AChE), which produces sustained acetylcholine stimulus of the 
muscarinic and nicotinic receptors and may lead to diaphragm incapacitation and suffocation. Biosensors 
containing enzymes inhibited by OPs have recently been explored for military and civilian applications 
(123, 129, 130).  
The human liver carboxylesterase 1 (hCE1) is a promiscuous serine hydrolase that catalyze the 
hydrolysis of endo- and xenobiotics containing ester, amide, or thioester bonds (120, 121, 131–135). This 
structural AChE homolog is currently being explored as prophylactic bioscavenger to decontaminate OP 
(136). Based upon the ability of hCE1 to bind Ops (133), we sought to determine whether silica 
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encapsulation of hCE1 would result in nanoparticles containing active enzyme and whether such particles 
could be employed to detect the presence of OP compounds.  
 
 
Materials and Methods 
Expression and purification of hCE1. A secreted form of hCE1 was expressed using Baculovirus 
in Spodptera frugiperda Sf21 cells and purified as described (Morton and Potter 2000). hCE1 was 
concentrated in 50 mM HEPES (pH 7.4) and stored at 4 
o
C. Protein concentration was determined 
spectrophotometrically using an extinction coefficient 17700 M
-1
 cm
-1
 (NanoDrop, ND-1000 
Spectrophotometer).  
Preparation of silica nanoparticles with hCE1. All materials were purchased from Sigma-Aldrich 
unless otherwise noted. A stock solution of lysozyme at 100 mg/ml was prepared in 0.1 M potassium 
phosphate buffer (pH 7.4). A solution of hydrolyzed tetramethylorthosilicate (TMOS) was freshly 
prepared by diluting into 1 mM hydrochloric acid to a final concentration of 1 M. A typical reaction 
mixture consisted of 800 µl of 0.1 M potassium phosphate buffer containing 5 µg of hCE1, 100 µl of 
lysozyme or R5 solution (100 mg/ml), and 100 µl of 1 M hydrolyzed TMOS. The mixture was incubated 
at room temperature (22 
o
C) for 10 minutes with gentle shaking. The slurry was centrifuged for 60 s 
(13,000 rpm) to remove the particles and washed in ddH2O three times. Control particles were produced 
in a similar manner using a reaction mixture without hCE1 by combining 800 µl of 0.1 M potassium 
phosphate buffer, 100 µl of lysozyme solution, and 100 µl of hydrolyzed TMOS. Combination particles 
were created using ratios of polyethyleneimine (1%) to lysozyme (100 mg/mL) 1:4, 1:1, 4:1 as the 
catalyst to compare the efficiency of enzyme incorporation. The total volume of catalyst used was always 
equal to 10% of the silica reaction.  
Scanning and transmission electron microscopy. The morphology of silica-encapsulated hCE1 
with various catalysts was observed with a Hitachi 4700 Scanning Electron Microscope (SEM) and a 
JEOL 2010F Transmission Electron Microscope (TEM). SEM samples were prepared by depositing dry 
powdered samples on a double-stick carbon tape on an aluminium SEM sample holder. The samples were 
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coated with a 3nm Au-Pd conductive coating in order to prevent charging effect during imaging. TEM 
samples were prepared by air drying a drop of concentrated reaction mixture on a carbon-stabilized 
copper grid (Ted Pella Inc.). 
Determination of hCE1 enzyme activity. Activity of silica-encapsulated or solution hCE1 were 
monitored using para-nitrophenyl butyrate (pNPB) as a substrate and measuring the absorbance of the 
para-nitrophenol product at 410 nm using a Pherastar spectrophotometer (BMG Labtech). The substrate 
was dissolved in ethanol to a concentration of 1 M, and then diluted to 10 mM in 0.1 M phosphate buffer 
pH 7.4. hCE1 silica particles were mixed with substrate at a final concentration of 5 mM. Supernatants 
from the washes were saved and monitored in the same fashion to determine the incorporation efficiency 
of the silica reactions.  
Kinetics of para-nitrophenyl butyrate hydrolysis.  Km, Vmax, and kcat values were determined by 
monitoring the conversions of para-nitrophenyl butyrate to nitrophenol product at 410 nm using a 
Pherastar spectrophotometer (BMG Labtech). Substrate was prepared the same way as described above. 
Data was collected over 4 minutes and the linear portions were used for the linear regressions to calculate 
the reaction velocities. Kinetic parameters were determined by fitting hyperbolic plots of reaction 
velocities versus substrate concentration. The Prism software packaged was used to fit the data 
(GraphPad, San Diego, CA). 
Column-based experiments. Column activity of silica-encapsulated hCE1 was determined using a 
stainless steel microbore column (2 cm x 2 mm, Upchurch Scientific, Oak Harbor, WA) with 0.5 µm frits. 
The silica nanoparticle reaction mixture was scaled up to a total of 10 mL. The particles were resuspended 
in 0.1 M phosphate buffer pH 7.4 and pumped at a flow rate of 10 µL/min to pack the column. The 
column was washed with 10 column volumes of phosphate buffer prior to use. All column experiments 
were performed at room temperature (22 
o
C) at a flow rate of 100 µL/min using a NE-1000 syringe pump 
(New Era Pump Systems, Wantagh, NY).  Phosphate buffer containing 5 mM substrate was flowed 
through the column. Samples were collected and analyzed in a Pherastar spectrophotometer to measure 
absorbance at 410 nm until the substrate hydrolysis had reached a maximum.  
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Organophosphate pesticide detection. Using a column constructed in the manner described 
above, phosphate buffer containing 5 mM substrate was applied and absorbance was measured until the 
substrate hydrolysis reached its maximum value. Phosphate buffer containing 5 mM substrate and 
paraoxon or DMPNPP (1mM) was then flowed through the column, and absorbance was measured to 
determine if OP was detected. The pesticides were diluted 1:10 in methanol and further diluted in 0.1 M 
phosphate buffer pH 7.4 to their final concentration. Inhibition was confirmed by flowing phosphate 
buffer containing 5 mM substrate through the column and monitoring absorbance at 410 nm. 
 
Results  
 
Silica Encapsulation of Active hCE1 
Initial experiments employed lysozyme as the polycation catalyst for silica nanoparticle 
formation in reaction conditions containing hydrolyzed tetramethylorthosilicate (TMOS), lysozyme (100 
mg/mL), and potassium phosphate buffer at pH 7.4 with 5 µg of hCE1 enzyme. Active hCE1was 
incorporated into the particles with high efficiency leaving no enzyme activity in the supernatant (Figure 
B.1A).  In addition, no hCE1 activity was detected in the supernatant around the particles or in the 
solutions used to wash the particles after formation (Figure B.1A).  hCE1 activity in the silica 
nanoparticles, as measured by para-nitrophenyl butyrate (pNPB) hydrolysis, reached the same maximal 
velocity as 5 µg of hCE1 in solution; however, the encapsulated enzyme exhibited a slightly reduced 
initial rate of product formation (Figure B.1A, Table B.1). Multiple washes of silica particles with 
phosphate buffer did not release active enzyme, indicating that the hCE1 activity associated with the silica 
particles did not arise from enzyme adhered to particle surfaces.   
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Figure B.1. Activity assays measuring the formation of para-nitrophenol at 410 nm. Silica particles 
were formed using the respective catalysts and the absorbance was measured over time. Activity was 
measured for the silica particles, and the supernatant from the reaction, and was compared to hCE1 
in solution.  
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Next we examined the effect of entrapping hCE1 in silica on the enzyme’s ability to hydrolyze 
substrate. Kinetic experiments were performed maintaining a constant amount of enzyme with varied 
substrate concentrations to determine initial reaction velocities. Michaelis-Menten kinetics were assumed 
and the kinetic parameters were determined (Table B.2).  hCE1 in silica had a Km that was approximately 
three times higher than in solution. Furthermore, hCE1 in silica was not as efficient when compared to 
solution as can be seen by the smaller kcat/Km values determine. These values are in agreement with 
previously reported kinetic parameters of hCE1 in solution with pNPB (137). Taken together, these 
results demonstrate that active hCE1 can be efficiently incorporated into lysozyme-catalyzed silica 
nanoparticles.  
 
 
 
Table B.1. hCE1 rate of 4-nitrophenyl butyrate hydrolysis in solution compared to silica particles 
created with different catalysts. NA: not applicable, no enzyme activity contained in the particles.  
Table B.2. Kinetic parameters for the metabolism of PNPB by hCE1 in solution and in  lysozyme 
catalyzed silica particles. 
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 We next investigated the ability of other cationic catalysts to generate hCE1-encapsulated silica 
nanoparticles. Silica particles were synthesized in the presence of hCE1using the following catalysts: 
cationic peptide R5 (NH2-SSKKSGSYSGSKGSKRRIL-CO2H) (138) and polyethyleneimine (PEI). Silica 
particles formed with the R5 peptide exhibited similar incorporation efficiency as well as hCE1 enzyme 
activity relative to the lysozyme silica particles (Figure B.1B, Table B.1).  In contrast, PEI catalyzed 
particles, which formed immediately upon mixing (compared to ~5 minutes with the lysozyme or R5 
silica particles) excluded hCE1 into the supernatant and thus had no associated enzyme activity with the 
particles. (Figure B.1C; Table B.1).  Moreover, the supernatant around the PEI catalyzed particles 
contained activity similar to the same amount hCE1 in solution. 
Next, we sought to improve incorporation efficiency by using a combination of lysozyme and PEI 
as a catalyst for our biosilicification reaction. We created beads using different ratios of lysozyme and 
PEI in the presence of the same amount of hCE1 (80% lysozyme:20% PEI, 50% lysozyme:50% PEI, and 
20% lysozyme:80% PEI). Increasing the amount of lysozyme relative to PEI improved the encapsulation 
of hCE1, but no silica particles that were formed in the presence of PEI exhibited higher levels of hCE1 
activity than those formed without PEI (Figures B.1D-F, Table B.1). Additionally, hCE1 alone could not 
facilitate the precipitation of silica particles without either lysozyme or the R5 peptide (data not shown).  
We cooled the reaction to 4C to see if we could slow the silica condensation in the presence of PEI. The 
reaction appeared to occur just as fast and no hCE1 was incorporated into the particles (Data not shown). 
Thus, macromolecular catalysts as small as the R5 peptide and as large as hen egg white lysozyme can 
mediate the formation of silica nanoparticles that encapsulate active hCE1.  
 
Electron Microscopy of hCE1 Nanoparticles   
Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) were 
employed in order to examine the size and morphology of silica particles produced in the presence of 
hCE1. Silica hCE1 particles using lysozyme as the catalyst were larger than the particles obtained using 
either R5 or PEI as catalysts. Lysozyme-catalyzed particles were 0.8-1 μm in diameter and appeared to 
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fuse to form large aggregates on the order of ~ 2 μm (Figure B.2A). In contrast, silica particles obtained 
in the presence of hCE1 using R5 and PEI as catalysts formed individual particles 0.3-0.8 μm in diameter 
and an aggregate size of ~ 1 μm (Figure B.2B, C). Dynamic light scattering (DLS) performed on the 
lysozyme catalyzed silica particles confirmed the sizes measured from SEM analysis (data not shown).  
The silica particles formed using the combinations of lysozyme and PEI were smaller (~ 0.5 μm) and 
appear monodisperse as compared to the particles using only lysozyme or PEI as catalysts (Figure B.2D, 
E, F). Increasing amounts of PEI in the reaction led to the formation of smaller particles and smaller 
aggregate size.   
 
 
 
TEM images corroborated the SEM data (Figure B.3A, B). For example, particles obtained in the 
presence of lysozyme were larger in size compared to that of the PEI-catalyzed silica particles. In 
Figure B.2. SEM images of the silica particles containing hCE1 at two magnifications. The samples 
were sputtered with Au-Pd conductive coating prior to analyses.  
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addition, the TEM images revealed that the lysozyme-catalyzed silica particles exhibited a smoother 
surface than that of the PEI-catalyzed particles. In contrast, the particles obtained using ratios of lysozyme 
and PEI as catalysts, appeared to have rougher surface features similar to that seen for the PEI catalyzed 
particles. This was presumably due to the presence of PEI on the particle surface (Figure B.3C, D and 
E).  
 
 
 
Solution Detection Studies with hCE1 Nanoparticles   
We examined whether silica nanoparticles containing active hCE1 could function in a column 
chromatography format.  Biosilica particles formed with lysozyme and hCE1 (see Figures B.1A, B.2A) 
Figure B.3. TEM images of the hCE1 encapsulated silica particles at two magnifications.  
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were packed using buffer flow into a stainless steel microbore column (2 cm x 2 mm) with 0.5 µm frits, 
and subsequent studies controlled using a New Era single syringe pump (New Era Pump Systems, 
Wantagh, NY).  Particles catalyzed with lysozyme in the presence of hCE1 were chosen because they 
were cost-effective and displayed robust entrapment efficiency and enzyme activity. After extensive 
washing of the column, pNPB was applied to the column and nitrophenol formation was observed, 
indicating that hCE1 retains its enzyme activity in the silica particles packed within the column (Figure 
B.4).  No hCE1 activity was detected in the solutions used to wash the column, supporting the conclusion 
that the enzyme remained encapsulated in the column particles (data not shown).   
 
 
 
We next investigated whether columns containing hCE1 biosilica nanoparticles were capable of 
detecting OP-pesticides.  Columns were operated in the manner described above, and equilibrated such 
Figure B.4. Microbore columns packed with silica particles catalyzed by lysozyme and containing 
hCE1 used to detect pesticides. The columns were equilibrated at 25 C to maximum activity before 
pesticide was applied (grey box). The eluant from the column was collected and measured in 
triplicate at the respective time points. 
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that a stable amount of para-nitrophenol product was being formed over time (e.g. 10 mol/min.). At that 
point, 1 mM diethyl para-nitrophenyl phosphate (paraoxon) was applied to a column, producing a 
dramatic drop in enzyme activity (Figure B.4A). Detection of the presence of this hCE1 inhibitor occurs 
rapidly, likely due to the small column volume of 16.2 L. hCE1 remains permanently inhibited by 
paraoxon even 50 minutes (~70 column volumes) after this inhibitor is removed from the substrate-
containing solution applied to the column (Figure B.4A).  In a second study, dimethyl-para-
nitrophenylphosphate (DMPNPP) was applied to a column instead of paraoxon. In this case, detection of 
the hCE1 inhibitor was rapid, but once the inhibitor was removed, hCE1 activity returned over time 
(Figure B.4B). Paraoxon inhibits hCE1 activity 3-fold more robustly in solution than DMPNPP (ki values 
of 9.1 ± 0.5 x 10
6 
min
-1
M
-1 
and 2.9 ± 0.3 x 10
6 
min
-1
M
-1
, respectively; data not shown).  Taken together, 
these results indicate that OP pesticides can be detected using hCE1 biosilica nanoparticles within a 
column chromatography format.  
 
Discussion  
Silica nanoparticles have the potential to generate a range of platforms for biodetection. We have 
shown that hCE1 can be effectively encapsulated into lysozyme-catalyzed silica nanoparticles, which 
maintain overall enzyme activity comparable to hCE1 in solution. However, they also exhibit a slightly 
reduced initial rate of product formation, although activity reached that of free hCE1 over time. We 
hypothesize that this effect is caused by impeded substrate access to the active site of the enzyme in the 
silica matrix. We also found that hCE1 is more efficiently incorporated into silica nanoparticles using 
lysozyme as a catalyst in comparison to PEI catalyzed silica particles. Similar results have been observed 
with other enzymes during encapsulation (126). 
In this work, however, we focused on three catalysts – lysozyme, the R5 peptide, and PEI – 
which have been demonstrated to be successful in previous studies with other target enzymes (129, 139, 
140). Based on our results (see Fig. B.1A-C, Table B.1), we hypothesize that the lack of entrapped hCE1 
during PEI-mediated particle creation was caused by the rapid particle formation and the small size of 
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PEI. For example, when lysozyme was used as a catalyst, the reaction proceeded slowly, taking 
approximately 2 minutes until particles can be visualized in solution; in contrast, when PEI was 
employed, the particles formed immediately. This observation, combined with the smaller sized PEI-
catalyzed particles relative to those created with lysozyme (see Fig. B.1A-C) suggested that PEI-
generated silica matrixes excluded hCE1 under the reaction conditions employed. The lysozyme-
catalyzed particles underwent more complete condensation, entrapping all the hCE1 present, similar to 
that seen for pure sol-gel silica reactions with other enzymes (141).  
Finally, we demonstrated that silica nanoparticles containing hCE1 are able to detect OP 
pesticides in a column chromatography format (see Fig. B.4).  The drop in hCE1 activity correlated with 
the strength of the inhibitor employed; for example, paraoxon, a more potent hCE1 inhibitor, did not 
allow enzyme activity to recover during the time course of the study. Such an apparatus could be 
employed in the detection of OP pesticides or chemical weapons agents using silica nanoparticles 
containing hCE1. Both liquid- and gas-based detection have already been reported involving other 
enzymes, including the cholinesterases (123).  Our data indicate that another member of the serine 
hydrolase family of enzymes may also be employed for this or related technologies.  
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